BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: von Minckwitz G, Huang C, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-salinas C, Wapnir IL, Jackisch C, Digiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019;380:617-28. [DOI: 10.1056/nejmoa1814017] [Cited by in Crossref: 584] [Cited by in F6Publishing: 245] [Article Influence: 194.7] [Reference Citation Analysis]
Number Citing Articles
1 Laakmann E, Emons J, Taran FA, Janni W, Uhrig S, Overkamp F, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Schulmeyer C, Müller V, Beckmann MW, Belleville E, Wimberger P, Hielscher C, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Volz B, Fasching PA, Fehm TN, Wallwiener D, Brucker SY, Schneeweiss A, Hartkopf AD. Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. Geburtshilfe Frauenheilkd 2020;80:1134-42. [PMID: 33173241 DOI: 10.1055/a-1286-2917] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 El Masri J, Phadke S. Breast Cancer Epidemiology and Contemporary Breast Cancer Care: A Review of the Literature and Clinical Applications. Clin Obstet Gynecol 2022. [PMID: 35703213 DOI: 10.1097/GRF.0000000000000721] [Reference Citation Analysis]
3 Younis T, Lee A, Coombes ME, Bouganim N, Becker D, Revil C, Jhuti GS. Economic evaluation of adjuvant trastuzumab emtansine in patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment in Canada. Curr Oncol 2020;27:e578-89. [PMID: 33380873 DOI: 10.3747/co.27.6517] [Reference Citation Analysis]
4 Stucci LS, Pisino M, D’addario C, Grassi T, Toss A. Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges. Front Oncol 2022;12:871160. [DOI: 10.3389/fonc.2022.871160] [Reference Citation Analysis]
5 Miglietta F, Bottosso M, Griguolo G, Dieci M, Guarneri V. Major advancements in metastatic breast cancer treatment: when expanding options means prolonging survival. ESMO Open 2022;7:100409. [DOI: 10.1016/j.esmoop.2022.100409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Tamirisa N, Hunt KK. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Ann Surg Oncol 2022;29:1489-92. [PMID: 34989940 DOI: 10.1245/s10434-021-11223-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, Mazzeo L, Rea CG, Mariani G, de Braud F, Bianchi GV, Vernieri C, Capri G. Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. Ther Adv Med Oncol 2020;12:1758835920970081. [PMID: 33335565 DOI: 10.1177/1758835920970081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Drago JZ, Ferraro E, Abuhadra N, Modi S. Beyond HER2: Targeting the ErbB receptor family in breast cancer. Cancer Treat Rev 2022;109:102436. [PMID: 35870237 DOI: 10.1016/j.ctrv.2022.102436] [Reference Citation Analysis]
9 Ulrich L, Okines AFC. Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib. Breast Cancer (Dove Med Press) 2021;13:361-81. [PMID: 34079368 DOI: 10.2147/BCTT.S268451] [Reference Citation Analysis]
10 Reinert T, de Souza ABA, Sartori GP, Obst FM, Barrios CH. Highlights of the 17th St Gallen International Breast Cancer Conference 2021: customising local and systemic therapies. Ecancermedicalscience 2021;15:1236. [PMID: 34221119 DOI: 10.3332/ecancer.2021.1236] [Reference Citation Analysis]
11 Khubchandani JA, Greenup RA. Time to surgery delays: Barriers to care for black women with breast cancer. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.05.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Trapani D, Curigliano G. Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021. Breast 2021:S0960-9776(21)01018-3. [PMID: 34920925 DOI: 10.1016/j.breast.2021.12.012] [Reference Citation Analysis]
13 Yao X, Li W, Li L, Li M, Zhao Y, Fang, Zeng X, Luo Z. YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis. Cell Death Dis 2022;13:258. [PMID: 35319018 DOI: 10.1038/s41419-022-04711-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Wadhwani N, Jatoi I. Overuse of Neo-adjuvant Chemotherapy for Primary Breast Cancer. Indian J Surg Oncol 2020;11:12-4. [PMID: 32205961 DOI: 10.1007/s13193-019-01002-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Krawczyk N, Fehm T, Ruckhaeberle E, Brus L, Kopperschmidt V, Rody A, Hanker L, Banys-Paluchowski M. Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies. Cancers (Basel) 2022;14:3002. [PMID: 35740667 DOI: 10.3390/cancers14123002] [Reference Citation Analysis]
16 Harbeck N. Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer. Breast 2022;62 Suppl 1:S12-6. [PMID: 35148934 DOI: 10.1016/j.breast.2022.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Jahan N, Rehman S, Khan R, Jones C. Relative Risk of Peripheral Neuropathy With Ado-Trastuzumab Emtansine (T-DM1) Compared to Taxane-Based Regimens in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Cancers: A Systematic Review and Meta-Analysis. Cureus 2021;13:e15282. [PMID: 34194883 DOI: 10.7759/cureus.15282] [Reference Citation Analysis]
18 Benguerfi S, Diéras V, Campone M, Mosnier JF, Robert M. Regenerative nodular hyperplasia after T-DM1: consequences from sinusoidal endothelium damages. Acta Oncol 2020;59:306-9. [PMID: 31556755 DOI: 10.1080/0284186X.2019.1670860] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Yu KD, Wang X, Chen WK, Fan L, Mo M, Chen H. Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer. NPJ Precis Oncol 2020;4:23. [PMID: 32802960 DOI: 10.1038/s41698-020-00128-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Kim M, Suh DH, Lee KH, Eom KY, Lee JY, Lee YY, Hansen HF, Mirza MR, Kim JW. Major clinical research advances in gynecologic cancer in 2019. J Gynecol Oncol 2020;31:e48. [PMID: 32319232 DOI: 10.3802/jgo.2020.31.e48] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
21 Li J, Zhang S, Ye C, Liu Q, Cheng Y, Ye J, Liu Y, Duan X, Xin L, Zhang H, Xu L. Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy. JPM 2022;12:261. [DOI: 10.3390/jpm12020261] [Reference Citation Analysis]
22 Hurvitz SA, Martin M, Jung KH, Huang CS, Harbeck N, Valero V, Stroyakovskiy D, Wildiers H, Campone M, Boileau JF, Fasching PA, Afenjar K, Spera G, Lopez-Valverde V, Song C, Trask P, Boulet T, Sparano JA, Symmans WF, Thompson AM, Slamon D. Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. J Clin Oncol. 2019;37:2206-2216. [PMID: 31157583 DOI: 10.1200/jco.19.00882] [Cited by in Crossref: 47] [Cited by in F6Publishing: 23] [Article Influence: 15.7] [Reference Citation Analysis]
23 Li L, Chen M, Zheng S, Li H, Chi W, Xiu B, Zhang Q, Hou J, Wang J, Wu J. Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy. Front Oncol 2021;11:592393. [PMID: 34336634 DOI: 10.3389/fonc.2021.592393] [Reference Citation Analysis]
24 Martin M, Hegg R, Kim SB, Schenker M, Grecea D, Garcia-Saenz JA, Papazisis K, Ouyang Q, Lacko A, Oksuzoglu B, Reeves J, Okera M, Testa L, Shimizu C, Denduluri N, Adamchuk H, Dakhil S, Wei R, Forrester T, Fernandez MM, Zimmermann A, Headley D, Johnston SRD. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial. JAMA Oncol 2022. [PMID: 35653145 DOI: 10.1001/jamaoncol.2022.1488] [Reference Citation Analysis]
25 Shin SH, Park YH, Park SS, Ju EJ, Park J, Ko EJ, Bae DJ, Kim SY, Chung CW, Song HY, Jang SJ, Jeong SY, Song SY, Choi EK. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers. Adv Sci (Weinh) 2021;8:e2102414. [PMID: 34664433 DOI: 10.1002/advs.202102414] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Lüftner D, Bauerfeind I, Braun M, Brucker SY, Fasching PA, Felberbaum R, Hagemann F, Haidinger R, Harbeck N, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thomssen C, Untch M, Wuerstlein R, Thill M. Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel) 2019;14:315-24. [PMID: 31798392 DOI: 10.1159/000502603] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Yu X, Wang C, Zheng Y, Miao B, Hu J, Shao X, Sheng L, Lin J, Ding Y, Xuan H, Ding Y, Gong L, Feng W, Qin C, Chen D, Yu Y, Yang H. Preoperative Systemic Therapy Versus Upfront Surgery in HER2-Positive Breast Cancer in the Real World. Front Oncol 2021;11:704842. [PMID: 34395277 DOI: 10.3389/fonc.2021.704842] [Reference Citation Analysis]
28 Prete SD, Montella L, Arpino G, Buono G, Buonerba C, Dolce P, Fiorentino O, Aliberti M, Febbraro A, Savastano C, Colantuoni G, Riccardi F, Ruggiero A, Placido S, Orditura M. Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. Oncotarget 2020;11:2083-91. [PMID: 32547706 DOI: 10.18632/oncotarget.27603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Conte P, Schneeweiss A, Loibl S, Mamounas EP, von Minckwitz G, Mano MS, Untch M, Huang CS, Wolmark N, Rastogi P, D'Hondt V, Redondo A, Stamatovic L, Bonnefoi H, Castro-Salguero H, Fischer HH, Wahl T, Song C, Boulet T, Trask P, Geyer CE Jr. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer. Cancer 2020;126:3132-9. [PMID: 32286687 DOI: 10.1002/cncr.32873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Wang Z, Wen Z, Liu L, Zhu X, Shen B, Yan X, Duan Y, Huang Y. Yangpumicins F and G, Enediyne Congeners from Micromonospora yangpuensis DSM 45577. J Nat Prod 2019;82:2483-8. [PMID: 31490685 DOI: 10.1021/acs.jnatprod.9b00229] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
31 Lim M, Nguyen TH, Niland C, Reid LE, Jat PS, Saunus JM, Lakhani SR. Landscape of Epidermal Growth Factor Receptor Heterodimers in Brain Metastases. Cancers 2022;14:533. [DOI: 10.3390/cancers14030533] [Reference Citation Analysis]
32 Diker O, Aktas BY, Ak R, Koylu B, Bas O, Taban H, Guven DC, Olgun P, Kertmen N, Dizdar O, Oksuzoglu B, Aksoy S. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience. Future Oncol 2021. [PMID: 34758639 DOI: 10.2217/fon-2021-0303] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Tafreshi NK, Morse DL, Lee MC. Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. World J Clin Oncol 2020; 11(4): 169-179 [PMID: 32355639 DOI: 10.5306/wjco.v11.i4.169] [Reference Citation Analysis]
34 Singer L, Weiss A, Bellon JR, King TA. Regional Nodal Management After Preoperative Systemic Therapy. Seminars in Radiation Oncology 2022;32:228-36. [DOI: 10.1016/j.semradonc.2022.01.003] [Reference Citation Analysis]
35 Ramtohul T, Tescher C, Vaflard P, Cyrta J, Girard N, Malhaire C, Tardivon A. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies. Radiology 2022;:220389. [PMID: 35880977 DOI: 10.1148/radiol.220389] [Reference Citation Analysis]
36 Cusano E, Wong C, Taguedong E, Vaska M, Abedin T, Nixon N, Karim S, Tang P, Heng DYC, Ezeife D. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Curr Oncol 2021;28:4894-928. [PMID: 34898590 DOI: 10.3390/curroncol28060412] [Reference Citation Analysis]
37 Allegretti M, Fabi A, Giordani E, Ercolani C, Romania P, Nisticò C, Gasparro S, Barberi V, Ciolina M, Pescarmona E, Giannarelli D, Ciliberto G, Cognetti F, Giacomini P. Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer. Mol Cancer 2021;20:151. [PMID: 34839818 DOI: 10.1186/s12943-021-01438-z] [Reference Citation Analysis]
38 Aragon-sanchez S, Oliver-perez MR, Madariaga A, Tabuenca MJ, Martinez M, Galindo A, Arroyo ML, Gallego M, Blanco M, Ciruelos-gil EM, Hu T. Accuracy and Limitations of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients with Positive Nodes. The Breast Journal 2022;2022:1-8. [DOI: 10.1155/2022/1507881] [Reference Citation Analysis]
39 Tokuchi K, Maeda T, Kitamura S, Yanagi T, Ujiie H. HER2-Targeted Antibody–Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget’s Disease Models: In Vivo and Immunohistochemical Analyses. Cancers 2022;14:3519. [DOI: 10.3390/cancers14143519] [Reference Citation Analysis]
40 Laws A, Pastorello R, Dey T, Grossmith S, King C, McGrath M, Schnitt SJ, Mittendorf EA, King T. Impact of the Histologic Pattern of Residual Tumor After Neoadjuvant Chemotherapy on Recurrence and Survival in Stage I-III Breast Cancer. Ann Surg Oncol 2022. [PMID: 35810224 DOI: 10.1245/s10434-022-12054-6] [Reference Citation Analysis]
41 Tian JH, Liu SH, Yu CY, Wu LG, Wang LB. The Role of Non-Coding RNAs in Breast Cancer Drug Resistance. Front Oncol 2021;11:702082. [PMID: 34589423 DOI: 10.3389/fonc.2021.702082] [Reference Citation Analysis]
42 Tarantino P, Gandini S, Nicolò E, Trillo P, Giugliano F, Zagami P, Vivanet G, Bellerba F, Trapani D, Marra A, Esposito A, Criscitiello C, Viale G, Curigliano G. Evolution of low HER2 expression between early and advanced-stage breast cancer. Eur J Cancer 2022;163:35-43. [PMID: 35032815 DOI: 10.1016/j.ejca.2021.12.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
43 Barok M, Puhka M, Yazdi N, Joensuu H. Extracellular vesicles as modifiers of antibody-drug conjugate efficacy. J Extracell Vesicles 2021;10:e12070. [PMID: 33613875 DOI: 10.1002/jev2.12070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Christian N, Ahrendt G. Axillary Primary and Breast Cancer Management. Curr Breast Cancer Rep 2021;13:42-8. [DOI: 10.1007/s12609-020-00400-0] [Reference Citation Analysis]
45 Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y, Yonemori K, Takayama S, Suto A. Breast Cancer Brain Metastasis-Overview of Disease State, Treatment Options and Future Perspectives. Cancers (Basel) 2021;13:1078. [PMID: 33802424 DOI: 10.3390/cancers13051078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Hua X, Duan F, Zhai W, Song C, Jiang C, Wang L, Huang J, Lin H, Yuan Z. A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Early-Stage Breast Cancer. JIR 2022;Volume 15:381-94. [DOI: 10.2147/jir.s338421] [Reference Citation Analysis]
47 Zhang J, Fan J, Zeng X, Nie M, Chen W, Wang Y, Luan J, Zhu Z, Chang X, Ju D, Feng L, Yin K. Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer. Cell Death Dis 2021;12:288. [PMID: 33731670 DOI: 10.1038/s41419-020-03349-1] [Reference Citation Analysis]
48 Mango VL, Pilewskie M, Jochelson MS. To Look or Not to Look? Axillary Imaging: Less May Be More. Journal of Breast Imaging 2021;3:666-71. [DOI: 10.1093/jbi/wbab075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Untch M, Loibl S, Fasching PA. Concerning Dediu M, Zielinski A: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer. Breast Care 2019; Doi 10.1159/000500620. Breast Care (Basel) 2020;15:96-101. [PMID: 32231504 DOI: 10.1159/000500624] [Reference Citation Analysis]
50 Chiec L, Kumthekar P. Targeting HER2+ Breast Cancer Brain Metastases: A Review of Brain-Directed HER2-Directed Therapies. CNS Drugs. [DOI: 10.1007/s40263-021-00894-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Waks AG, Desai NV, Li T, Poorvu PD, Partridge AH, Sinclair N, Spring LM, Faggen M, Constantine M, Metzger O, Alberti J, Deane J, Rosenberg SM, Frank E, Tolaney SM, Krop IE, Tung NM, Tayob N, King TA, Mittendorf EA, Winer EP. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. NPJ Breast Cancer 2022;8:63. [PMID: 35538105 DOI: 10.1038/s41523-022-00429-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Laws A, Specht MC. Leveraging Neoadjuvant Chemotherapy to Minimize the Burden of Axillary Surgery: a Review of Current Strategies and Surgical Techniques. Curr Breast Cancer Rep 2020;12:317-25. [DOI: 10.1007/s12609-020-00388-7] [Reference Citation Analysis]
53 Rushton M, Lima I, Tuna M, Johnson C, Ivars J, Pritchard K, Hawken S, Dent S. Impact of Stopping Trastuzumab in Early Breast Cancer: A Population-Based Study in Ontario, Canada. J Natl Cancer Inst 2020;112:1222-30. [PMID: 32343801 DOI: 10.1093/jnci/djaa054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
54 Griguolo G, Brasó-Maristany F, González-Farré B, Pascual T, Chic N, Saurí T, Kates R, Gluz O, Martínez D, Paré L, Tsvetkova V, Pesantez D, Vidal M, Adamo B, Muñoz M, Galván P, Barberá L, Cuatrecasas M, Christgen M, Kreipe H, Monge-Escartín I, Villagrasa P, Soy D, Giarratano T, Dieci MV, Conte P, Harbeck N, Guarneri V, Prat A. ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer. Cancers (Basel) 2020;12:E1902. [PMID: 32674482 DOI: 10.3390/cancers12071902] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
55 Mano MS. Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor-Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems. Breast 2020;54:331-4. [PMID: 33279792 DOI: 10.1016/j.breast.2020.11.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Vignoli A, Risi E, McCartney A, Migliaccio I, Moretti E, Malorni L, Luchinat C, Biganzoli L, Tenori L. Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. Int J Mol Sci 2021;22:4687. [PMID: 33925233 DOI: 10.3390/ijms22094687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Gupta G, Lee CD, Guye ML, Van Sciver RE, Lee MP, Lafever AC, Pang A, Tang-Tan AM, Winston JS, Samli B, Jansen RJ, Hoefer RA, Tang AH. Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. Ann Breast Cancer Ther 2020;4:48-57. [PMID: 32542231 DOI: 10.36959/739/525] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Bianchini G, Arpino G, Biganzoli L, Lonardi S, Puglisi F, Santini D, Lambertini M, Pappagallo G. Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel. Cancers 2022;14:1022. [DOI: 10.3390/cancers14041022] [Reference Citation Analysis]
59 Hartmann S, Stachs A, Schultek G, Gerber B, Reimer T. The Clinical Relevance of Target Lymph Node Biopsy after Primary Systemic Therapy in Initially Node-Positive Breast Cancer Patients. Cancers (Basel) 2021;13:2620. [PMID: 34073547 DOI: 10.3390/cancers13112620] [Reference Citation Analysis]
60 Liu H, Wang G. MicroRNA-301a-3p promotes triple-negative breast cancer progression through downregulating MEOX2. Exp Ther Med 2021;22:945. [PMID: 34306209 DOI: 10.3892/etm.2021.10377] [Reference Citation Analysis]
61 Smith BD, Goetz MP, Boughey JC. Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement. J Clin Oncol 2020;38:2290-8. [PMID: 32442073 DOI: 10.1200/JCO.19.03036] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Rinnerthaler G, Gampenrieder SP, Greil R. HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer. Int J Mol Sci 2019;20:E1115. [PMID: 30841523 DOI: 10.3390/ijms20051115] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 17.0] [Reference Citation Analysis]
63 Martelli V, Latocca MM, Ruelle T, Perachino M, Arecco L, Beshiri K, Razeti MG, Tagliamento M, Cosso M, Fregatti P, Lambertini M. Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women. Breast Cancer (Dove Med Press) 2021;13:341-51. [PMID: 34079366 DOI: 10.2147/BCTT.S274283] [Reference Citation Analysis]
64 Maddox AL, Brehove MS, Eliato KR, Saftics A, Romano E, Press MF, Mortimer J, Jones V, Schmolze D, Seewaldt VL, Jovanovic-talisman T. Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer. Cancers 2022;14:2795. [DOI: 10.3390/cancers14112795] [Reference Citation Analysis]
65 Brandão M, Caparica R, Malorni L, Prat A, Carey LA, Piccart M. What Is the Real Impact of Estrogen Receptor Status on the Prognosis and Treatment of HER2-Positive Early Breast Cancer? Clin Cancer Res 2020;26:2783-8. [PMID: 32046997 DOI: 10.1158/1078-0432.CCR-19-2612] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
66 Balic M, Thomssen C, Würstlein R, Gnant M, Harbeck N. St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. Breast Care (Basel) 2019;14:103-10. [PMID: 31798382 DOI: 10.1159/000499931] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 18.7] [Reference Citation Analysis]
67 Kufel-Grabowska J, Podolak A, Maliszewski D, Bartoszkiewicz M, Ramlau R, Lukaszuk K. Fertility Counseling in BRCA1/2-Mutated Women with Breast Cancer and Healthy Individuals. J Clin Med 2022;11:3996. [PMID: 35887761 DOI: 10.3390/jcm11143996] [Reference Citation Analysis]
68 Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, Winer E, Partridge A, Perou CM, Carey LA. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol 2020;38:4184-93. [PMID: 33095682 DOI: 10.1200/JCO.20.01276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
69 Lam DL, Parker EU, Kim JN, Yung RL, Flanagan MR. A Multidisciplinary Approach to Managing Uncertainty. Curr Breast Cancer Rep 2021;13:365-80. [DOI: 10.1007/s12609-021-00437-9] [Reference Citation Analysis]
70 Krystel-Whittemore M, Xu J, Brogi E, Ventura K, Patil S, Ross DS, Dang C, Robson M, Norton L, Morrow M, Wen HY. Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy. Breast Cancer Res Treat 2019;177:61-6. [PMID: 31144151 DOI: 10.1007/s10549-019-05295-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
71 Kerr AJ, Dodwell D, Mcgale P, Holt F, Duane F, Mannu G, Darby SC, Taylor CW. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102375] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Grandal B, Mangiardi-Veltin M, Laas E, Laé M, Meseure D, Bataillon G, El-Alam E, Darrigues L, Dumas E, Daoud E, Vincent-Salomon A, Talagrand LS, Pierga JY, Reyal F, Hamy AS. PD-L1 Expression after Neoadjuvant Chemotherapy in Triple-Negative Breast Cancers Is Associated with Aggressive Residual Disease, Suggesting a Potential for Immunotherapy. Cancers (Basel) 2021;13:746. [PMID: 33670162 DOI: 10.3390/cancers13040746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Ditsch N, Untch M, Thill M, Müller V, Janni W, Albert US, Bauerfeind I, Blohmer J, Budach W, Dall P, Diel I, Fasching PA, Fehm T, Friedrich M, Gerber B, Hanf V, Harbeck N, Huober J, Jackisch C, Kolberg-Liedtke C, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Möbus V, Müller-Schimpfle M, Mundhenke C, Nitz U, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Wenz F, Witzel I, Wöckel A. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019;14:224-45. [PMID: 31558897 DOI: 10.1159/000501000] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
74 Shohdy KS, Almeldin DS, Fekry MA, Ismail MA, AboElmaaref NA, ElSadany EG, Hamza BM, El-Shorbagy FH, Ali AS, Attia H, Kassem L. Pathological responses and survival outcomes in patients with locally advanced breast cancer after neoadjuvant chemotherapy: a single-institute experience. J Egypt Natl Canc Inst 2021;33:39. [PMID: 34905125 DOI: 10.1186/s43046-021-00096-y] [Reference Citation Analysis]
75 Riecke K, Witzel I. Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2. Breast Care (Basel) 2020;15:579-85. [PMID: 33447231 DOI: 10.1159/000510998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Carter RR, Chum AP, Sanchez R, Guha A, Dey AK, Reinbolt R, Kim L, Otchere P, Oppong-Nkrumah O, Abraham WT, Lustberg M, Addison D. Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control. Cancer Med 2022. [PMID: 35633055 DOI: 10.1002/cam4.4862] [Reference Citation Analysis]
77 Theocharopoulos C, Lialios PP, Gogas H, Ziogas DC. An overview of antibody-drug conjugates in oncological practice. Ther Adv Med Oncol 2020;12:1758835920962997. [PMID: 33088347 DOI: 10.1177/1758835920962997] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E. The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial. Mol Oncol 2021. [PMID: 34816585 DOI: 10.1002/1878-0261.13141] [Reference Citation Analysis]
79 Kashyap AS, Fernandez-rodriguez L, Zhao Y, Monaco G, Trefny MP, Yoshida N, Martin K, Sharma A, Olieric N, Shah P, Stanczak M, Kirchhammer N, Park S, Wieckowski S, Laubli H, Zagani R, Kasenda B, Steinmetz MO, Reinecker H, Zippelius A. GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses. Cell Reports 2019;28:3367-3380.e8. [DOI: 10.1016/j.celrep.2019.08.057] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
80 Moss NS, Tosi U, Santomasso BD, Beal K, Modi S. Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan. CNS Oncol 2022;11:CNS90. [PMID: 35674041 DOI: 10.2217/cns-2022-0010] [Reference Citation Analysis]
81 Manspeaker MP, Thomas SN. Lymphatic immunomodulation using engineered drug delivery systems for cancer immunotherapy. Adv Drug Deliv Rev 2020;160:19-35. [PMID: 33058931 DOI: 10.1016/j.addr.2020.10.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
82 Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A. Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials. Cancers (Basel) 2021;13:5198. [PMID: 34680350 DOI: 10.3390/cancers13205198] [Reference Citation Analysis]
83 Kim JW, Cho YB, Lee S. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021;10:670. [PMID: 33802964 DOI: 10.3390/cells10030670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Ceci C, Lacal PM, Graziani G. Antibody-drug conjugates: Resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther 2022;236:108106. [PMID: 34990642 DOI: 10.1016/j.pharmthera.2021.108106] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
85 Nakhlis F, Portnow L, Gombos E, Daylan AEC, Leone JP, Kantor O, Richardson ET, Ho A, Dunn SA, Ohri N. Multidisciplinary Considerations in the Management of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Current Problems in Surgery 2022. [DOI: 10.1016/j.cpsurg.2022.101191] [Reference Citation Analysis]
86 Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, Kuroi K, Yasojima H, Kasai H, Takasuka T, Sakurai T, Kataoka TR, Morita S, Ohno S, Toi M. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer. Breast Cancer Res Treat 2020;180:135-46. [PMID: 31953696 DOI: 10.1007/s10549-020-05524-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
87 Pistelli M, Merloni F, Crocetti S, Scortichini L, Tassone L, Cantini L, Agostinelli V, Bastianelli L, Savini A, Berardi R. Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience. J Oncol 2021;2021:5548252. [PMID: 34054952 DOI: 10.1155/2021/5548252] [Reference Citation Analysis]
88 Corti C, Antonarelli G, Valenza C, Nicolò E, Rugo H, Cortés J, Harbeck N, Carey LA, Criscitiello C, Curigliano G. Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? Eur J Cancer 2022;171:25-42. [PMID: 35696887 DOI: 10.1016/j.ejca.2022.04.039] [Reference Citation Analysis]
89 Mills MN, Walker C, Thawani C, Naz A, Figura NB, Kushchayev S, Etame A, Yu HM, Robinson TJ, Liu J, Vogelbaum MA, Forsyth PA, Czerniecki BJ, Soliman HH, Han HS, Ahmed KA. Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases. BMC Cancer 2021;21:223. [PMID: 33663447 DOI: 10.1186/s12885-021-07971-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Conte B, Montemurro F, Levaggi A, Blondeaux E, Molinelli C, Cardinali B, Poggio F, Buzzatti G, Bighin C, Lambertini M, Del Mastro L. Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial. Tumori 2022;:3008916211067568. [PMID: 34989265 DOI: 10.1177/03008916211067568] [Reference Citation Analysis]
91 Laas E, Bresset A, Féron JG, Le Gal C, Darrigues L, Coussy F, Grandal B, Laot L, Pierga JY, Reyal F, Hamy AS. HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens. Cancers (Basel) 2021;13:370. [PMID: 33498405 DOI: 10.3390/cancers13030370] [Reference Citation Analysis]
92 Hyder T, Bhattacharya S, Gade K, Nasrazadani A, Brufsky AM. Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. Breast Cancer (Dove Med Press) 2021;13:199-211. [PMID: 33833568 DOI: 10.2147/BCTT.S273058] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Zhang L, Shen D, Yu L, Yan Y, Wasan HS, Yu J, Zhang S, Sun L. Is antibody-drug conjugate a rising star for clinical treatment of solid tumors? A systematic review and meta-analysis. Crit Rev Oncol Hematol 2022;177:103758. [PMID: 35868498 DOI: 10.1016/j.critrevonc.2022.103758] [Reference Citation Analysis]
94 Zhang I, Barac A. Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction. Curr Oncol Rep 2022. [PMID: 35362825 DOI: 10.1007/s11912-022-01234-y] [Reference Citation Analysis]
95 Shen G, Zhao F, Huo X, Ren D, Du F, Zheng F, Zhao J. Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment. Front Oncol 2021;11:632357. [PMID: 34367947 DOI: 10.3389/fonc.2021.632357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Lutrino ES, Orlando L, Febbraro A, Giampaglia M, Zamagni C, Schiavone P, Scavelli C, Dima G, Fedele P, Giordano G, Bilancia D, Quaranta AM, Rubino D, Filippelli G, Fontanella C, Caliolo C, Marino A, Calvani N, Ferrara P, Cinieri S. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. Tumori 2020;106:301-5. [PMID: 31847742 DOI: 10.1177/0300891619887225] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
97 Chatzipli A, Bonnefoi H, MacGrogan G, Sentis J, Cameron D, Poncet C, Iggo R; EORTC 10994/BIG 1-00 Consortium. Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. Br J Cancer 2021;125:1356-64. [PMID: 34480095 DOI: 10.1038/s41416-021-01526-3] [Reference Citation Analysis]
98 Skarping I, Larsson M, Förnvik D. Analysis of mammograms using artificial intelligence to predict response to neoadjuvant chemotherapy in breast cancer patients: proof of concept. Eur Radiol 2021. [PMID: 34652522 DOI: 10.1007/s00330-021-08306-w] [Reference Citation Analysis]
99 Bruzas S, Gluz O, Harbeck N, Schmid P, Cortés J, Blohmer J, Seiberling C, Chiari O, Harrach H, Ataseven B, Shenoy S, Dyson MH, Traut E, Theuerkauf I, Gebauer D, Kuemmel S, Reinisch M. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. npj Breast Cancer 2022;8. [DOI: 10.1038/s41523-022-00403-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Martín-Sabroso C, Lozza I, Torres-Suárez AI, Fraguas-Sánchez AI. Antibody-Antineoplastic Conjugates in Gynecological Malignancies: Current Status and Future Perspectives. Pharmaceutics 2021;13:1705. [PMID: 34683998 DOI: 10.3390/pharmaceutics13101705] [Reference Citation Analysis]
101 Kaplan HG, Malmgren JA, Guo B, Atwood MK. Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018. Breast Cancer Res Treat. [DOI: 10.1007/s10549-022-06678-1] [Reference Citation Analysis]
102 Patel A, Unni N, Peng Y. The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer. Cancers (Basel) 2020;12:E2081. [PMID: 32731409 DOI: 10.3390/cancers12082081] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
103 Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto W, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, Yu J, Chiang V, Nakano T, Aoyama H, Mehta MP. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. Int J Radiat Oncol Biol Phys 2020;107:334-43. [PMID: 32084525 DOI: 10.1016/j.ijrobp.2020.01.051] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
104 Chen C, Ding Y, Liu H, Sun M, Wang H, Wu D. Flubendazole Plays an Important Anti-Tumor Role in Different Types of Cancers. Int J Mol Sci 2022;23:519. [PMID: 35008943 DOI: 10.3390/ijms23010519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Solinas C, Fumagalli D, Dieci MV. Immune Checkpoint Blockade in HER2-Positive Breast Cancer: What Role in Early Disease Setting? Cancers (Basel) 2021;13:1655. [PMID: 33916115 DOI: 10.3390/cancers13071655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
106 Al-Hilli Z, Weiss A, Armani A, Boughey JC, Blair SL. Breast cancer-The catalyst of contemporary trials design. J Surg Oncol 2022;125:7-16. [PMID: 34897706 DOI: 10.1002/jso.26722] [Reference Citation Analysis]
107 Tokunaga E, Masuda N, Yamamoto N, Iwata H, Bando H, Aruga T, Ohtani S, Fujisawa T, Takano T, Inoue K, Suganuma N, Takada M, Aogi K, Sakurai K, Shigematsu H, Kuroi K, Haga H, Ohno S, Morita S, Toi M. Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study). Cancers (Basel) 2021;13:4008. [PMID: 34439165 DOI: 10.3390/cancers13164008] [Reference Citation Analysis]
108 Li K, Liao N, Chen B, Zhang G, Wang Y, Guo L, Wei G, Jia M, Wen L, Ren C, Cao L, Mok H, Li C, Lin J, Chen X, Zhang Z, Hou T, Li M, Liu J, Balch CM, Liao N. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy. Breast Cancer Res Treat 2020;183:321-32. [PMID: 32638235 DOI: 10.1007/s10549-020-05778-0] [Reference Citation Analysis]
109 Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol. 2020;17:233-250. [PMID: 31836877 DOI: 10.1038/s41571-019-0299-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
110 Regan MM. Accelerating progress to innovation for patients: Trial design and risk stratification. Breast 2021:S0960-9776(21)00993-0. [PMID: 34836764 DOI: 10.1016/j.breast.2021.11.010] [Reference Citation Analysis]
111 Isca C, Piacentini F, Mastrolia I, Masciale V, Caggia F, Toss A, Piombino C, Moscetti L, Barbolini M, Maur M, Dominici M, Omarini C. Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature. Cancers (Basel) 2021;13:4894. [PMID: 34638377 DOI: 10.3390/cancers13194894] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Battisti NML, Joshi K, Nasser MS, Ring A. Systemic therapy for older patients with early breast cancer. Cancer Treat Rev 2021;100:102292. [PMID: 34536728 DOI: 10.1016/j.ctrv.2021.102292] [Reference Citation Analysis]
113 Rivier C, Mery B, Rowinski E, Sotton S, Bouleftour W, Bertoletti L, Tredan O, Magne N. Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. Expert Opin Drug Saf 2021;:1-13. [PMID: 34551666 DOI: 10.1080/14740338.2021.1983541] [Reference Citation Analysis]
114 Ligorio F, Zambelli L, Fucà G, Lobefaro R, Santamaria M, Zattarin E, de Braud F, Vernieri C. Prognostic impact of body mass index (BMI) in HER2+ breast cancer treated with anti-HER2 therapies: from preclinical rationale to clinical implications. Ther Adv Med Oncol 2022;14:175883592210791. [DOI: 10.1177/17588359221079123] [Reference Citation Analysis]
115 González AF, Garcia PE, Gastaldo AS, Simón IS, Boffil JS, Borrego MR. Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure. Cancer Treat Res Commun 2021;27:100314. [PMID: 33545569 DOI: 10.1016/j.ctarc.2021.100314] [Reference Citation Analysis]
116 Bear HD, McGuire KP. Sentinel Node Biopsy After Neoadjuvant Systemic Therapy for Breast Cancer: The Method Matters. Ann Surg Oncol 2019;26:2316-8. [PMID: 31020504 DOI: 10.1245/s10434-019-07401-z] [Reference Citation Analysis]
117 Tse T, Sehdev S, Seely J, Gravel DH, Clemons M, Cordeiro E, Arnaout A. Neoadjuvant Chemotherapy in Breast Cancer: Review of the Evidence and Conditions That Facilitated Its Use during the Global Pandemic. Curr Oncol 2021;28:1338-47. [PMID: 33805031 DOI: 10.3390/curroncol28020127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS One 2020;15:e0234191. [PMID: 32579551 DOI: 10.1371/journal.pone.0234191] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
119 Bodet ML, Rouzier R, Héquet D. Rate of pathological complete response in early HER2 breast cancer. Bull Cancer 2022:S0007-4551(22)00120-5. [PMID: 35562230 DOI: 10.1016/j.bulcan.2022.02.016] [Reference Citation Analysis]
120 Sussell JA, Roth JA, Meyer CS, Fung A, Hansen SA. Assessment of the Cost-Effectiveness of HER2-Targeted Treatment Pathways in the Neoadjuvant Treatment of High-Risk HER2-Positive Early-Stage Breast Cancer. Adv Ther 2022;39:1375-92. [PMID: 35094298 DOI: 10.1007/s12325-022-02047-y] [Reference Citation Analysis]
121 Trabulsi NH, Shabkah AA, Ujaimi R, Iskanderani O, Kadi MS, Aljabri N, Sharbatly L, AlOtaibi MN, Farsi AH, Nassif MO, Saleem AM, Akeel NY, Malibary NH, Samkari AA. Locally Advanced Breast Cancer: Treatment Patterns and Predictors of Survival in a Saudi Tertiary Center. Cureus 2021;13:e15526. [PMID: 34277162 DOI: 10.7759/cureus.15526] [Reference Citation Analysis]
122 Pusch R. Neoadjuvant treatment in solid tumors—the earlier, the better in breast cancer. memo. [DOI: 10.1007/s12254-022-00819-4] [Reference Citation Analysis]
123 Kaur M, Kaur M, Bandopadhyay T, Sharma A, Priya A, Singh A, Banerjee B. Naturally occurring, natural product inspired and synthetic heterocyclic anti-cancer drugs. Physical Sciences Reviews 2022;0. [DOI: 10.1515/psr-2022-0003] [Reference Citation Analysis]
124 Asazuma K, Shimomura A, Shimizu C. Antibody-Drug Conjugates as an Adjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. J Clin Oncol 2022;:JCO2200135. [PMID: 35420886 DOI: 10.1200/JCO.22.00135] [Reference Citation Analysis]
125 Zhang J, Yu Y, Lin Y, Kang S, Lv X, Liu Y, Lin J, Wang J, Song C. Efficacy and safety of neoadjuvant therapy for HER2-positive early breast cancer: a network meta-analysis. Ther Adv Med Oncol 2021;13:17588359211006948. [PMID: 33868462 DOI: 10.1177/17588359211006948] [Reference Citation Analysis]
126 Huober J, Barrios CH, Niikura N, Jarząb M, Chang YC, Huggins-Puhalla SL, Pedrini J, Zhukova L, Graupner V, Eiger D, Henschel V, Gochitashvili N, Lambertini C, Restuccia E, Zhang H. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol 2022;:JCO2102772. [PMID: 35763704 DOI: 10.1200/JCO.21.02772] [Reference Citation Analysis]
127 Endo Y, Mohan N, Dokmanovic M, Wu WJ. Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities. Antib Ther 2021;4:55-9. [PMID: 33937626 DOI: 10.1093/abt/tbab005] [Reference Citation Analysis]
128 Linehan AS, Fitzpatrick OM, Morris PG. Profile of Trastuzumab Deruxtecan in the Management of Patients with HER2-Positive Unresectable or Metastatic Breast Cancer: An Evidence-Based Review. Breast Cancer (Dove Med Press) 2021;13:151-9. [PMID: 33658846 DOI: 10.2147/BCTT.S245024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Tan Y, Chen Q, Pan S, An W, Xu H, Xing Y, Zhang J. LMOD1, an oncogene associated with Lauren classification, regulates the metastasis of gastric cancer cells through the FAK-AKT/mTOR pathway. BMC Cancer 2022;22:474. [PMID: 35488236 DOI: 10.1186/s12885-022-09541-0] [Reference Citation Analysis]
130 Corti C, Criscitiello C. Tucatinib approval by EMA expands options for HER2-positive locally advanced or metastatic breast cancer. ESMO Open 2021;6:100063. [PMID: 33676293 DOI: 10.1016/j.esmoop.2021.100063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Ramamoorthi G, Kodumudi K, Snyder C, Grover P, Zhang H, Greene MI, Basu A, Gallen C, Wiener D, Costa RLB, Han HS, Koski G, Czerniecki BJ. Intratumoral delivery of dendritic cells plus anti-HER2 therapy triggers both robust systemic antitumor immunity and complete regression in HER2 mammary carcinoma. J Immunother Cancer 2022;10:e004841. [PMID: 35710296 DOI: 10.1136/jitc-2022-004841] [Reference Citation Analysis]
132 Ozaki Y, Miura S, Oki R, Morikawa T, Uchino K. Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature. Cancers (Basel) 2021;14:196. [PMID: 35008357 DOI: 10.3390/cancers14010196] [Reference Citation Analysis]
133 McAndrew NP. Updates on targeting human epidermal growth factor receptor 2-positive breast cancer: what's to know in 2021. Curr Opin Obstet Gynecol 2022;34:41-5. [PMID: 34967814 DOI: 10.1097/GCO.0000000000000762] [Reference Citation Analysis]
134 Sardesai S, Sukumar J, Kassem M, Palettas M, Stephens J, Morgan E, Addison D, Baliga R, Stover DG, VanDeusen J, Williams N, Cherian M, Lustberg M, Wesolowski R, Ramaswamy B. Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer. Cardiooncology 2020;6:26. [PMID: 33292843 DOI: 10.1186/s40959-020-00081-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Marumoto AD, Giuliano AE. Locoregional Management of Breast Cancer Following Neoadjuvant Chemotherapy. Curr Breast Cancer Rep. [DOI: 10.1007/s12609-022-00452-4] [Reference Citation Analysis]
136 Wang W, Guo B, Cui C, Sun T, Liu S. Management of early-stage breast cancer patients during the coronavirus disease 2019 (COVID-19) pandemic: The experience in China from a surgical standpoint. J Cancer 2021;12:2190-8. [PMID: 33758597 DOI: 10.7150/jca.50501] [Reference Citation Analysis]
137 Tanaka M, Shimomura A, Terakado H, Shimizu C. Adjuvant Treatment for Small-Size, Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Escalation or De-Escalation? J Clin Oncol 2021;39:3647-8. [PMID: 34506214 DOI: 10.1200/JCO.21.01716] [Reference Citation Analysis]
138 Futamura M, Oba M, Masuda N, Bando H, Okada M, Yamamoto Y, Kin T, Saeki T, Nagashima T, Kuwayama T, Toh U, Hirano A, Inokuchi M, Yamagami K, Mizuno Y, Kojima Y, Nakayama T, Yasojima H, Ohno S. Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study). Breast Cancer 2021;28:1023-37. [PMID: 33811599 DOI: 10.1007/s12282-021-01238-9] [Reference Citation Analysis]
139 Zeng J, Ma W, Young RB, Li T. Targeting HER2 genomic alterations in non-small cell lung cancer. Journal of the National Cancer Center 2021;1:58-73. [DOI: 10.1016/j.jncc.2021.04.001] [Reference Citation Analysis]
140 Untch M, Fasching PA, Brucker SY, Budach W, Denkert C, Haidinger R, Huober J, Jackisch C, Janni W, Kolberg-Liedtke C, Krug D, Kühn T, Loibl S, Lüftner D, Müller V, Schneeweiss A, Thill M, Harbeck N, Thomssen C. Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference. Geburtshilfe Frauenheilkd 2021;81:637-53. [PMID: 34168378 DOI: 10.1055/a-1483-2782] [Reference Citation Analysis]
141 Copeland J, Oyedeji A, Powell N, Cherian CJ, Tokumaru Y, Murthy V, Takabe K, Young J. Breast Cancer in Jamaica: Stage, Grade and Molecular Subtype Distributions Across Age Blocks, the Implications for Screening and Treatment. World J Oncol 2021;12:93-103. [PMID: 34349853 DOI: 10.14740/wjon1389] [Reference Citation Analysis]
142 Maadi H, Soheilifar MH, Choi WS, Moshtaghian A, Wang Z. Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. Cancers (Basel) 2021;13:3540. [PMID: 34298754 DOI: 10.3390/cancers13143540] [Reference Citation Analysis]
143 Huang Z, Jin S, Zeng M, Shu J, Liu Y, Zhang J, Xu B, Niu M, Sun S, Nanding A, Shan M, Li X, Zhang G. Clinical and Therapeutic Factors Vary by Prognosis in Patients with Pathological Complete Response After Neoadjuvant Therapy for Breast Cancer. CMAR 2021;Volume 13:9235-46. [DOI: 10.2147/cmar.s338589] [Reference Citation Analysis]
144 Agostinetto E, Montemurro F, Puglisi F, Criscitiello C, Bianchini G, Del Mastro L, Introna M, Tondini C, Santoro A, Zambelli A. Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers (Basel) 2022;14:2136. [PMID: 35565264 DOI: 10.3390/cancers14092136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Metz G, Snook K, Sood S, Baron-hay S, Spillane A, Lamoury G, Carroll S. Breast Radiotherapy after Oncoplastic Surgery—A Multidisciplinary Approach. Cancers 2022;14:1685. [DOI: 10.3390/cancers14071685] [Reference Citation Analysis]
146 D'Amico S, Krasnowska EK, Manni I, Toietta G, Baldari S, Piaggio G, Ranalli M, Gambacurta A, Vernieri C, Di Giacinto F, Bernassola F, de Braud F, Lucibello M. DHA Affects Microtubule Dynamics Through Reduction of Phospho-TCTP Levels and Enhances the Antiproliferative Effect of T-DM1 in Trastuzumab-Resistant HER2-Positive Breast Cancer Cell Lines. Cells 2020;9:E1260. [PMID: 32438775 DOI: 10.3390/cells9051260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
147 Zong Y, Pegram M. Research advances and new challenges in overcoming triple-negative breast cancer. Cancer Drug Resist 2021;4:517-42. [PMID: 34888495 DOI: 10.20517/cdr.2021.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
148 Hurvitz SA, Saura C, Oliveira M, Trudeau ME, Moy B, Delaloge S, Gradishar W, Kim SB, Haley B, Ryvo L, Dai MS, Milovanov V, Alarcón J, Kalmadi S, Cronemberger E, Souza C, Landeiro L, Bose R, Bebchuk J, Kabbinavar F, Bryce R, Keyvanjah K, Brufsky AM. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. Oncologist 2021;26:e1327-38. [PMID: 34028126 DOI: 10.1002/onco.13830] [Reference Citation Analysis]
149 Brandão M, Reyal F, Hamy AS, Piccart-Gebhart M. Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation. ESMO Open 2019;4:e000515. [PMID: 31231570 DOI: 10.1136/esmoopen-2019-000515] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
150 Mousavi I, Olivier T, Prasad V. Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022. JAMA Netw Open 2022;5:e2216058. [PMID: 35687338 DOI: 10.1001/jamanetworkopen.2022.16058] [Reference Citation Analysis]
151 Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-Drug Conjugates: The Last Decade. Pharmaceuticals (Basel) 2020;13:E245. [PMID: 32937862 DOI: 10.3390/ph13090245] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 23.0] [Reference Citation Analysis]
152 Wang X, Xu W, Liu Z, Wu Y, Wang Q, Cao M, Ying T, He N, Lu L, Jiang S. A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. mBio 2022;:e0338421. [PMID: 35038908 DOI: 10.1128/mbio.03384-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
153 Zheng S, Li L, Chen M, Yang B, Chen J, Liu G, Shao Z, Wu J. Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC. Breast 2022;63:177-86. [PMID: 35429731 DOI: 10.1016/j.breast.2022.03.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Bertucci A, Bertucci F, Zemmour C, Lerebours F, Pierga JY, Levy C, Dalenc F, Grenier J, Petit T, Berline M, Gonçalves A. PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. Front Oncol 2020;10:575978. [PMID: 33330051 DOI: 10.3389/fonc.2020.575978] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
155 Simmons C, Rayson D, Joy AA, Henning JW, Lemieux J, McArthur H, Card PB, Dent R, Brezden-Masley C. Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines. Ther Adv Med Oncol 2022;14:17588359211066677. [PMID: 35035535 DOI: 10.1177/17588359211066677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
156 Marhold M, Topakian T, Agis H, Bartsch R, Berghoff AS, Brodowicz T, Fuereder T, Ilhan-Mutlu A, Kiesewetter B, Krainer M, Locker GJ, Marosi C, Prager G, Schmidinger M, Thallinger C, Zöchbauer-Müller S, Raderer M, Preusser M, Lamm W. Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field. ESMO Open 2020;5:e000880. [PMID: 33051192 DOI: 10.1136/esmoopen-2020-000880] [Reference Citation Analysis]
157 Zattarin E, Leporati R, Ligorio F, Lobefaro R, Vingiani A, Pruneri G, Vernieri C. Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications. Cells 2020;9:E2644. [PMID: 33316954 DOI: 10.3390/cells9122644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
158 Xu C, Liu S, Yang F, Zhang K, Li Y, Zhao X, Zhang J, Lu T, Lu S, Jiang Y, Qin W, Shi C, Zhang R, Yang AG, Zhao A, Han D, Wen W. Antibody-drug conjugates targeting CD248+ myofibroblasts effectively alleviate renal fibrosis in mice. FASEB J 2022;36:e22102. [PMID: 34972243 DOI: 10.1096/fj.202101441R] [Reference Citation Analysis]
159 Ma W, Yang Y, Zhu J, Jia W, Zhang T, Liu Z, Chen X, Lin Y. Biomimetic Nanoerythrosome-Coated Aptamer-DNA Tetrahedron/Maytansine Conjugates: pH-Responsive and Targeted Cytotoxicity for HER2-Positive Breast Cancer. Adv Mater 2022;:e2109609. [PMID: 35064993 DOI: 10.1002/adma.202109609] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
160 Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol 2021;14:20. [PMID: 33509252 DOI: 10.1186/s13045-021-01035-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
161 Yu J, Li NL. Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report. World J Clin Cases 2022; 10(17): 5923-5928 [DOI: 10.12998/wjcc.v10.i17.5923] [Reference Citation Analysis]
162 Parisi F, Razeti MG, Blondeaux E, Arecco L, Perachino M, Tagliamento M, Levaggi A, Fregatti P, Poggio F, Lambertini M. Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. Clin Med Insights Oncol 2020;14:1179554920931816. [PMID: 32647477 DOI: 10.1177/1179554920931816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
163 Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer 2022;8:18. [PMID: 35173164 DOI: 10.1038/s41523-022-00385-2] [Reference Citation Analysis]
164 Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S. BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. Diagnostics (Basel) 2020;10:E119. [PMID: 32098267 DOI: 10.3390/diagnostics10020119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
165 Brezden-Masley C, Fathers KE, Coombes ME, Pourmirza B, Xue C, Jerzak KJ. A population-based comparison of treatment, resource utilization, and costs by cancer stage for Ontario patients with HER2-positive breast cancer. Breast Cancer Res Treat 2021;185:807-15. [PMID: 33090268 DOI: 10.1007/s10549-020-05976-w] [Reference Citation Analysis]
166 Kolberg HC, Schneeweiss A, Fehm TN, Wöckel A, Huober J, Pontones C, Titzmann A, Belleville E, Lux MP, Janni W, Hartkopf AD, Taran FA, Wallwiener M, Overkamp F, Tesch H, Ettl J, Lüftner D, Müller V, Schütz F, Fasching PA, Brucker SY. Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd 2019;79:470-82. [PMID: 31148847 DOI: 10.1055/a-0887-0861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
167 Huebner H, Kurbacher CM, Kuesters G, Hartkopf AD, Lux MP, Huober J, Volz B, Taran FA, Overkamp F, Tesch H, Häberle L, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Ruebner M, Untch M, Fasching PA, Janni W, Fehm TN, Kolberg HC, Wallwiener D, Brucker SY, Schneeweiss A, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC Cancer 2020;20:1091. [PMID: 33176725 DOI: 10.1186/s12885-020-07546-1] [Reference Citation Analysis]
168 Bou Zerdan M, Ghorayeb T, Saliba F, Allam S, Bou Zerdan M, Yaghi M, Bilani N, Jaafar R, Nahleh Z. Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021. Cancers (Basel) 2022;14:1253. [PMID: 35267561 DOI: 10.3390/cancers14051253] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
169 Yee D, DeMichele AM, Yau C, Isaacs C, Symmans WF, Albain KS, Chen YY, Krings G, Wei S, Harada S, Datnow B, Fadare O, Klein M, Pambuccian S, Chen B, Adamson K, Sams S, Mhawech-Fauceglia P, Magliocco A, Feldman M, Rendi M, Sattar H, Zeck J, Ocal IT, Tawfik O, LeBeau LG, Sahoo S, Vinh T, Chien AJ, Forero-Torres A, Stringer-Reasor E, Wallace AM, Pusztai L, Boughey JC, Ellis ED, Elias AD, Lu J, Lang JE, Han HS, Clark AS, Nanda R, Northfelt DW, Khan QJ, Viscusi RK, Euhus DM, Edmiston KK, Chui SY, Kemmer K, Park JW, Liu MC, Olopade O, Leyland-Jones B, Tripathy D, Moulder SL, Rugo HS, Schwab R, Lo S, Helsten T, Beckwith H, Haugen P, Hylton NM, Van't Veer LJ, Perlmutter J, Melisko ME, Wilson A, Peterson G, Asare AL, Buxton MB, Paoloni M, Clennell JL, Hirst GL, Singhrao R, Steeg K, Matthews JB, Asare SM, Sanil A, Berry SM, Esserman LJ, Berry DA; I-SPY2 Trial Consortium. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol 2020;6:1355-62. [PMID: 32701140 DOI: 10.1001/jamaoncol.2020.2535] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
170 Bešlija S, Gojković Z, Cerić T, Mekić Abazović A, Marijanović I, Vranić S, Mustedanagić-Mujanović J, Skenderi F, Rakita I, Guzijan A, Koprić D, Humačkić A, Trokić D, Alidžanović J, Efendić A, Šišić I, Drljević H, Bešlagić V, Babić B, Pašić A, Ramić A, Mikić D, Guzin Z, Karan D, Buhovac T, Miletić D, Šečić S, Đozić Šahmić A, Mujbegović L, Kubura A, Burina M, Lalović N, Dukić N, Vladičić Mašić J, Ćuk M, Stanušić R. 2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina. Bosn J Basic Med Sci 2021;21:120-35. [PMID: 32415816 DOI: 10.17305/bjbms.2020.4846] [Reference Citation Analysis]
171 Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Pernas S, Gavila J, Guarnieri V, Cortes J, Villagrasa P, Chic N, Vidal M, Adamo B, Muñoz M, Griguolo G, Llombart A, Conte P, Oliveira M, Conte B, Paré L, Galvan P, Carey LA, Perou CM, Prat A. Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. Clin Cancer Res 2021;27:3116-25. [PMID: 33632929 DOI: 10.1158/1078-0432.CCR-20-4102] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Hardy-Werbin M, Quiroga V, Cirauqui B, Romeo M, Felip E, Teruel I, Garcia JJ, Erasun C, España S, Cucurull M, Montprade E, Pardo JC, Carballo D, Velarde JM, Margeli M. Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep 2019;9:12760. [PMID: 31484985 DOI: 10.1038/s41598-019-49251-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
173 Mailhot Vega RB, Wang S, Brooks ED, Oladeru OT, Lockney NA, Spiguel LE, MacDonald SM, Mamounas EP, Mendenhall NP, Okunieff PG, Lee JH, Bradley JA. Evaluating Regional Nodal Irradiation Allocation and Association with Oncologic Outcomes in NSABP B-18, B-27, B-40, and B-41. Int J Radiat Oncol Biol Phys 2022:S0360-3016(22)00240-1. [PMID: 35418342 DOI: 10.1016/j.ijrobp.2022.03.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Orlando L, Lorusso V, Giotta F, Di Maio M, Schiavone P, Fedele P, Quaranta A, Caliolo C, Ciccarese M, Cinefra M, Romito S, Pisconti S, Prete SD, Aieta M, Rizzi D, Maiello E, Colucci G, Cinieri S. Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). Breast 2020;53:18-22. [PMID: 32540553 DOI: 10.1016/j.breast.2020.06.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
175 Ha JY, Kim JE, Lee HJ, Jeong JH, Ahn JH, Jung KH, Gong G, Chae EY, Kim HH, Chung IY, Ko BS, Kim SB. Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab. J Breast Cancer 2021;24:359-66. [PMID: 34352937 DOI: 10.4048/jbc.2021.24.e36] [Reference Citation Analysis]
176 Blaes AH, Dang C. Trastuzumab: Weighing the Benefits and the Risks. J Natl Cancer Inst 2020;112:1181-2. [PMID: 32343773 DOI: 10.1093/jnci/djaa055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
177 Zhao H, Han B, Li X, Sun C, Zhai Y, Li M, Jiang M, Zhang W, Liang Y, Kai G. Salvia miltiorrhiza in Breast Cancer Treatment: A Review of Its Phytochemistry, Derivatives, Nanoparticles, and Potential Mechanisms. Front Pharmacol 2022;13:872085. [DOI: 10.3389/fphar.2022.872085] [Reference Citation Analysis]
178 Li J, Jiang Z. Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification. Cancer Biol Med 2022:j. [PMID: 35765123 DOI: 10.20892/j.issn.2095-3941.2022.0277] [Reference Citation Analysis]
179 Hasegawa Y, Matsubara N, Kogawa T, Naito Y, Harano K, Hosono A, Onishi T, Hojo T, Shimokawa M, Mukohara T. Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy. In Vivo 2021;35:1041-9. [PMID: 33622900 DOI: 10.21873/invivo.12348] [Reference Citation Analysis]
180 Gutnik L, Fayanju OM. Controversies in Breast Cancer Surgery. Surg Clin North Am 2021;101:1033-44. [PMID: 34774266 DOI: 10.1016/j.suc.2021.06.002] [Reference Citation Analysis]
181 Li X, Tan Q, Li H, Yang X. Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis. Cancer Manag Res 2021;13:5889-98. [PMID: 34349562 DOI: 10.2147/CMAR.S313123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer. Oncologist 2020;25:e1355-62. [PMID: 32618068 DOI: 10.1634/theoncologist.2020-0201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
183 Maire M, Debled M, Petit A, Fournier M, Macgrogan G, Quenel-Thueux N, Charitansky H, Mathoulin-Pelissier S, Bonnefoi H, Tunon de Lara C. Neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer: Safety and efficacy of reverse sequence compared to standard technique? Eur J Surg Oncol 2022:S0748-7983(22)00415-2. [PMID: 35523623 DOI: 10.1016/j.ejso.2022.04.022] [Reference Citation Analysis]
184 Koirala N, Dey N, Aske J, De P. Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. Int J Mol Sci 2022;23:6547. [PMID: 35742993 DOI: 10.3390/ijms23126547] [Reference Citation Analysis]
185 Li F, Ju Q, Gao C, Li J, Wang X, Yan M, Zhang L, Huang M, Long Q, Jin X, Li N. Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab. Front Oncol 2022;12:819818. [DOI: 10.3389/fonc.2022.819818] [Reference Citation Analysis]
186 Barmettler G, Williams MD, Cortina CS. Modern Management of Chest Wall Recurrences after Mastectomy. Curr Breast Cancer Rep. [DOI: 10.1007/s12609-022-00454-2] [Reference Citation Analysis]
187 Wu J, Kong R, Tian S, Li H, Wu K, Kong L. Can trastuzumab emtansine be replaced by additional chemotherapy plus targeted therapy for HER2-overexpressing breast cancer patients with residual disease after neoadjuvant chemotherapy? Chin J Cancer Res 2019;31:878-91. [PMID: 31949390 DOI: 10.21147/j.issn.1000-9604.2019.06.04] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
188 Lattanzi M, Rosenberg JE. The emerging role of antibody-drug conjugates in urothelial carcinoma. Expert Rev Anticancer Ther 2020;20:551-61. [PMID: 32552213 DOI: 10.1080/14737140.2020.1782201] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
189 Beddok A, Cottu P, Fourquet A, Kirova Y. Combination of Modern Radiotherapy and New Targeted Treatments for Breast Cancer Management. Cancers (Basel) 2021;13:6358. [PMID: 34944978 DOI: 10.3390/cancers13246358] [Reference Citation Analysis]
190 Le D, Eslami M, Li H, Hajjaj O, Chia S, Simmons C. Does the time from diagnostic biopsy to neoadjuvant chemotherapy affect the rate of pathologic complete response in stages I-III breast cancer? Curr Oncol 2020;27:e265-70. [PMID: 32669932 DOI: 10.3747/co.27.5907] [Reference Citation Analysis]
191 Boix-Montesinos P, Soriano-Teruel PM, Armiñán A, Orzáez M, Vicent MJ. The past, present, and future of breast cancer models for nanomedicine development. Adv Drug Deliv Rev 2021;173:306-30. [PMID: 33798642 DOI: 10.1016/j.addr.2021.03.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 19.0] [Reference Citation Analysis]
192 Corbin KS, Breen WG, Strauss JB. Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1). Clin Transl Radiat Oncol 2020;24:99-101. [PMID: 32715108 DOI: 10.1016/j.ctro.2020.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
193 Wu J, Luo M, Chen Z, Li L, Huang X. Integrated Analysis of the Expression Characteristics, Prognostic Value, and Immune Characteristics of PPARG in Breast Cancer. Front Genet 2021;12:737656. [PMID: 34567087 DOI: 10.3389/fgene.2021.737656] [Reference Citation Analysis]
194 Coelho S, Rego IB, Dionísio MR, Cavaco-Silva J, Semedo PM, Pavão F, Leite RB, Costa L. 360 Health Analysis (H360) - A Proposal for an Integrated Vision of Breast Cancer in Portugal. Eur J Breast Health 2020;16:91-8. [PMID: 32285029 DOI: 10.5152/ejbh.2020.5144] [Reference Citation Analysis]
195 Schuster S, Juhász É, Halmos G, Neundorf I, Gennari C, Mező G. Development and Biochemical Characterization of Self-Immolative Linker Containing GnRH-III-Drug Conjugates. Int J Mol Sci 2022;23:5071. [PMID: 35563462 DOI: 10.3390/ijms23095071] [Reference Citation Analysis]
196 Liao H, Huang W, Liu Y, Pei W, Li H. Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis. Front Oncol 2021;11:608781. [PMID: 34012912 DOI: 10.3389/fonc.2021.608781] [Reference Citation Analysis]
197 Jagosky M, Tan AR. Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data. Breast Cancer (Dove Med Press) 2021;13:393-407. [PMID: 34163239 DOI: 10.2147/BCTT.S176514] [Reference Citation Analysis]
198 Potter DA, Herrera-Ponzanelli CA, Hinojosa D, Castillo R, Hernandez-Cruz I, Arrieta VA, Franklin MJ, Yee D. Recent advances in neoadjuvant therapy for breast cancer. Fac Rev 2021;10:2. [PMID: 33659921 DOI: 10.12703/r/10-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
199 O'Sullivan CC, Ballman KV, McCall L, Kommalapati A, Zemla T, Weiss A, Mitchell M, Blinder V, Tung NM, Irvin WJ, Lee M, Goetz MP, Symmans WF, Borges VF, Krop I, Carey LA, Partridge AH. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Future Oncol 2021;17:4665-76. [PMID: 34636255 DOI: 10.2217/fon-2021-0753] [Reference Citation Analysis]
200 Harbeck N, von Schumann R, Kates RE, Braun M, Kuemmel S, Schumacher C, Potenberg J, Malter W, Augustin D, Aktas B, Forstbauer H, Tio J, Grischke EM, Biehl C, Liedtke C, De Haas SL, Deurloo R, Wuerstlein R, Kreipe HH, Gluz O. Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers (Basel) 2021;13:4884. [PMID: 34638369 DOI: 10.3390/cancers13194884] [Reference Citation Analysis]
201 Thanopoulou E, Khader L, Caira M, Wardley A, Ettl J, Miglietta F, Neven P, Guarneri V. Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature. Cancers (Basel) 2020;12:E3317. [PMID: 33182657 DOI: 10.3390/cancers12113317] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
202 Si Z, Zhang S, Yang X, Ding N, Xiang M, Zhu Q, Mao Y, Lv Y, Yu L, Shang H, Xie J, Tian Y. The Association Between the Incidence Risk of Peripheral Neuropathy and PD-1/PD-L1 Inhibitors in the Treatment for Solid Tumor Patients: A Systematic Review and Meta-Analysis. Front Oncol 2019;9:866. [PMID: 31552184 DOI: 10.3389/fonc.2019.00866] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
203 Paluch-Shimon S, Cherny NI, de Vries EGE, Dafni U, Piccart MJ, Latino NJ, Cardoso F. Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies. ESMO Open 2020;5:e000743. [PMID: 32893189 DOI: 10.1136/esmoopen-2020-000743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
204 Lerebours F, Cabel L, Pierga JY. Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art. Cancers (Basel) 2021;13:902. [PMID: 33670042 DOI: 10.3390/cancers13040902] [Reference Citation Analysis]
205 Noronha J, Joshi S, Hawaldar R, Nair N, Vanmali V, Parmar V, Shet T, Badwe R. Sterilization Rate of the Axilla After Neoadjuvant Chemotherapy: The Scope for Conservative Surgery. JCO Glob Oncol 2020;6:1184-91. [PMID: 32735491 DOI: 10.1200/GO.20.00195] [Reference Citation Analysis]
206 Kris MG, Faivre-Finn C, Kordbacheh T, Chaft J, Luo J, Tsao A, Swisher S. Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book 2020;40:1-12. [PMID: 32298162 DOI: 10.1200/EDBK_280807] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
207 Smrke A, Anderson PM, Gulia A, Gennatas S, Huang PH, Jones RL. Future Directions in the Treatment of Osteosarcoma. Cells 2021;10:172. [PMID: 33467756 DOI: 10.3390/cells10010172] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
208 Mo H, Jazieh KA, Brinzevich D, Abraham J. A Review of Treatment-Induced Pulmonary Toxicity in Breast Cancer. Clin Breast Cancer 2021:S1526-8209(21)00142-7. [PMID: 34226162 DOI: 10.1016/j.clbc.2021.05.014] [Reference Citation Analysis]
209 Tarantino P, Tolaney SM, Harbeck N, Cortes J, Curigliano G. Anthracyclines for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Are We Ready to Let Them Go? J Clin Oncol 2021;39:3541-5. [PMID: 34406849 DOI: 10.1200/JCO.21.01059] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
210 Spring LM, Specht MC, Jimenez RB, Isakoff SJ, Wang GX, Ly A, Shin JA, Bardia A, Moy B. Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. N Engl J Med 2020;383:262-72. [PMID: 32610007 DOI: 10.1056/NEJMcpc2002422] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
211 Bueno Muiño C, Martín M, Del Monte-Millán M, García-Saénz JÁ, López-Tarruella S. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping. Cancers (Basel) 2022;14:512. [PMID: 35158778 DOI: 10.3390/cancers14030512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Earl H, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Rea D, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mahler-Araujo B, Provenzano E, Chhabra A, Gasson S, Balmer C, Abraham JE, Caldas C, Hall P, Shinkins B, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA. Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technol Assess 2020;24:1-190. [PMID: 32880572 DOI: 10.3310/hta24400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
213 Tang C, He Z, Liu H, Xu Y, Huang H, Yang G, Xiao Z, Li S, Liu H, Deng Y, Chen Z, Chen H, He N. Application of magnetic nanoparticles in nucleic acid detection. J Nanobiotechnology 2020;18:62. [PMID: 32316985 DOI: 10.1186/s12951-020-00613-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 5] [Article Influence: 9.5] [Reference Citation Analysis]
214 Tasoulis MK, Heil J, Kuerer HM. De-escalating Surgery Among Patients with HER2 + and Triple Negative Breast Cancer. Curr Breast Cancer Rep 2022;:1-7. [PMID: 35915668 DOI: 10.1007/s12609-022-00453-3] [Reference Citation Analysis]
215 Caparica R, Ma Y, De Angelis C, Richard F, Desmedt C, Awada A, Piccart M, Perez EA, Moreno-Aspitia A, Badve S, Thompson EA, de Azambuja E. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial. Clin Breast Cancer 2021:S1526-8209(21)00351-7. [PMID: 34980541 DOI: 10.1016/j.clbc.2021.11.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
216 Liotta LA, Pappalardo PA, Carpino A, Haymond A, Howard M, Espina V, Wulfkuhle J, Petricoin E. Laser Capture Proteomics: Spatial Tissue Molecular Profiling from the bench to personalized medicine. Expert Rev Proteomics 2021. [PMID: 34607525 DOI: 10.1080/14789450.2021.1984886] [Reference Citation Analysis]
217 Weiss A, King TA. What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer? Advances in Surgery 2022. [DOI: 10.1016/j.yasu.2022.02.008] [Reference Citation Analysis]
218 Diao K, Andring LM, Barcenas CH, Singh P, Le-Petross H, Reed VK, Reddy JP, Bloom ES, Ahmad NR, Mayo LL, Perkins GH, Mitchell MP, Nead KT, Tereffe W, Smith BD, Woodward WA. Contemporary Outcomes after Multimodality Therapy in Breast Cancer Patients Presenting with Ipsilateral Supraclavicular Node Involvement. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02714-0. [PMID: 34710521 DOI: 10.1016/j.ijrobp.2021.08.026] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 McCaffrey RL, Thompson JL, Oudsema RH, Sciallis AP, Cobain EF, Sabel MS, Jeruss JS. Management of early stage HER2 positive breast cancer and increased implementation of axillary imaging to improve identification of nodal metastasis. J Surg Oncol 2022. [PMID: 35230701 DOI: 10.1002/jso.26840] [Reference Citation Analysis]
220 Nahvi I, Belkahla S, Biswas S, Chakraborty S. A Review on Nanocarrier Mediated Treatment and Management of Triple Negative Breast Cancer: A Saudi Arabian Scenario. Front Oncol 2022;12:953865. [DOI: 10.3389/fonc.2022.953865] [Reference Citation Analysis]
221 Bossuyt V, Spring L. Pathologic evaluation of response to neoadjuvant therapy drives treatment changes and improves long-term outcomes for breast cancer patients. Breast J 2020;26:1189-98. [PMID: 32468652 DOI: 10.1111/tbj.13864] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 He L, Wu Q, Xiong J, Su Z, Zhang B, Song Y. Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis. Cancer Manag Res 2019;11:8043-54. [PMID: 31507328 DOI: 10.2147/CMAR.S208319] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
223 Kang MS, Kong TWS, Khoo JYX, Loh TP. Recent developments in chemical conjugation strategies targeting native amino acids in proteins and their applications in antibody-drug conjugates. Chem Sci 2021;12:13613-47. [PMID: 34760149 DOI: 10.1039/d1sc02973h] [Reference Citation Analysis]
224 Stoeber R. Role of WDR5 in breast cancer prognosis. EXCLI J 2019;18:1094-6. [PMID: 31938027 DOI: 10.17179/excli2019-2062] [Reference Citation Analysis]
225 Acevedo F, Petric M, Walbaum B, Robin J, Legorburu L, Murature G, Guerra C, Navarro M, Canovas MJ, Sanchez C, Vargas L, Manzor M, Peña J, Muñiz S, Veglia P, Cartes R, Martinez R. Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital. Ecancermedicalscience 2021;15:1185. [PMID: 33777178 DOI: 10.3332/ecancer.2021.1185] [Reference Citation Analysis]
226 Huang YH, Chu PY, Chen JL, Huang CT, Huang CC, Tsai YF, Wang YL, Lien PJ, Tseng LM, Liu CY. Expression pattern and prognostic impact of glycoprotein non-metastatic B (GPNMB) in triple-negative breast cancer. Sci Rep 2021;11:12171. [PMID: 34108545 DOI: 10.1038/s41598-021-91588-3] [Reference Citation Analysis]
227 Hong J, Park YH. Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer. Ther Adv Med Oncol 2022;14:17588359221106564. [PMID: 35756967 DOI: 10.1177/17588359221106564] [Reference Citation Analysis]
228 Kruse ML, Kang IM, Bagegni NA, Howell WT, Moore HCF, Bedell CH, Stokoe CT. Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature. Oncol Ther 2021. [PMID: 34800263 DOI: 10.1007/s40487-021-00178-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Chainitikun S, Saleem S, Lim B, Valero V, Ueno NT. Update on systemic treatment for newly diagnosed inflammatory breast cancer. J Adv Res 2021;29:1-12. [PMID: 33842000 DOI: 10.1016/j.jare.2020.08.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
230 Gril B, Wei D, Zimmer AS, Robinson C, Khan I, Difilippantonio S, Overstreet MG, Steeg PS. HER2 antibody-drug conjugate controls growth of breast cancer brain metastases in hematogenous xenograft models, with heterogeneous blood-tumor barrier penetration unlinked to a passive marker. Neuro Oncol 2020;22:1625-36. [PMID: 32386414 DOI: 10.1093/neuonc/noaa118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
231 Schick J, Ritchie RP, Restini C. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer (Auckl) 2021;15:1178223421995854. [PMID: 33994789 DOI: 10.1177/1178223421995854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
232 Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Nabieva N, Taran FA, Ettl J, Lüftner D, Belleville E, Schütz F, Fasching PA, Fehm TN, Kolberg HC, Overkamp F, Schneeweiss A, Tesch H. Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd 2019;79:256-67. [PMID: 30880824 DOI: 10.1055/a-0842-6614] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
233 Lv M, Guo H, Wang C, Tian P, Ma Y, Chen X, Luo S. Neoadjuvant docetaxel with or without carboplatin plus dual HER2 blockade for HER2-positive breast cancer: a retrospective multi-center Chinese study. Gland Surg 2020;9:2079-90. [PMID: 33447559 DOI: 10.21037/gs-20-791] [Reference Citation Analysis]
234 Vanguri RS, Fenn KM, Kearney MR, Wang Q, Guo H, Marks DK, Chin C, Alcus CF, Thompson JB, Leu C, Hibshoosh H, Kalinsky KM, Mathews JC, Nadeem S, Hollmann TJ, Connolly EP. Tumor immune microenvironment and response to neoadjuvant chemotherapy in hormone receptor/HER2+ early stage breast cancer. Clinical Breast Cancer 2022. [DOI: 10.1016/j.clbc.2022.04.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Tesch ME, Partridge AH. Treatment of Breast Cancer in Young Adults. Am Soc Clin Oncol Educ Book 2022;42:1-12. [PMID: 35580291 DOI: 10.1200/EDBK_360970] [Reference Citation Analysis]
236 Liu C, Zhao Z, Gao R, Zhang X, Sun Y, Wu J, Liu J, Chen C. Matrix Metalloproteinase-2-Responsive Surface-Changeable Liposomes Decorated by Multifunctional Peptides to Overcome the Drug Resistance of Triple-Negative Breast Cancer through Enhanced Targeting and Penetrability. ACS Biomater Sci Eng 2022;8:2979-94. [PMID: 35666956 DOI: 10.1021/acsbiomaterials.2c00295] [Reference Citation Analysis]
237 Eiger D, Franzoi MA, Pondé N, Brandão M, de Angelis C, Schmitt Nogueira M, de Hemptinne Q, de Azambuja E. Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO Open 2020;5:e000659. [PMID: 32079624 DOI: 10.1136/esmoopen-2019-000659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
238 Gameiro A, Urbano AC, Ferreira F. Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma. Vet Sci 2021;8:164. [PMID: 34437486 DOI: 10.3390/vetsci8080164] [Reference Citation Analysis]
239 Lux MP, Schneeweiss A, Hartkopf AD, Müller V, Janni W, Belleville E, Stickeler E, Thill M, Fasching PA, Kolberg HC, Untch M, Harbeck N, Wöckel A, Thomssen C, Schulmeyer CE, Welslau M, Overkamp F, Schütz F, Lüftner D, Ditsch N. Update Breast Cancer 2020 Part 5 - Moving Therapies From Advanced to Early Breast Cancer Patients. Geburtshilfe Frauenheilkd 2021;81:469-80. [PMID: 33867564 DOI: 10.1055/a-1397-7170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Huober J, Schneeweiss A, Hartkopf AD, Müller V, Lux MP, Janni W, Ettl J, Belleville E, Thill M, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Tesch H, Fehm TN, Lüftner D, Schütz F, Wöckel A. Update Breast Cancer 2020 Part 3 - Early Breast Cancer. Geburtshilfe Frauenheilkd 2020;80:1105-14. [PMID: 33173238 DOI: 10.1055/a-1270-7208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
241 Rao M, Dhanushkodi M. Locally Advanced Breast Cancer—A Narrative Review of Management in the Indian Scenario. Indian J Med Paediatr Oncol 2021;42:137-45. [DOI: 10.1055/s-0041-1732785] [Reference Citation Analysis]
242 Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. Breast Cancer (Auckl) 2020;14:1178223420980377. [PMID: 33402827 DOI: 10.1177/1178223420980377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
243 Haque W, Verma V, Schwartz MR, Lim B, Mangalampalli N, Butler EB, Teh BS. Neoadjuvant Chemotherapy for Metaplastic Breast Cancer: Response Rates, Management, and Outcomes. Clinical Breast Cancer 2022. [DOI: 10.1016/j.clbc.2022.01.006] [Reference Citation Analysis]
244 Coiro S, Gasparini E, Falco G, Santandrea G, Foroni M, Besutti G, Iotti V, Di Cicilia R, Foroni M, Mele S, Ferrari G, Bisagni G, Ragazzi M. Biomarkers Changes after Neoadjuvant Chemotherapy in Breast Cancer: A Seven-Year Single Institution Experience. Diagnostics 2021;11:2249. [DOI: 10.3390/diagnostics11122249] [Reference Citation Analysis]
245 Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. [DOI: 10.1136/bmj-2021-066381] [Reference Citation Analysis]
246 Tang SC, Capra CL, Ajebo GH, Meza-Junco J, Mairs S, Craft BS, Zhu X, Maihle N, Hillegass WB. Systemic toxicities of trastuzumab-emtansine predict tumor response in HER2+ metastatic breast cancer. Int J Cancer 2021. [PMID: 33844843 DOI: 10.1002/ijc.33597] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
247 Spring LM, Bar Y, Isakoff SJ. The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer. J Natl Compr Canc Netw 2022;20:723-34. [PMID: 35714678 DOI: 10.6004/jnccn.2022.7016] [Reference Citation Analysis]
248 Oki N, Seki H, Sakurai T, Horiuchi Y, Kodaka K, Shimizu K. Intramedullary spinal cord metastasis to the cauda equina in a patient with HER2-positive metastatic breast cancer: A case report. BD 2022;41:155-61. [DOI: 10.3233/bd-210032] [Reference Citation Analysis]
249 Nelson B, Brizendine AM, Gietzen R, Venkatesan R. Case of HER2neu+ Invasive Pleomorphic Lobular Carcinoma With Response to Conventional Neoadjuvant Chemotherapy: A Viable Option for an Exceedingly Rare Breast Cancer Type. Cureus 2020;12:e11108. [PMID: 33240704 DOI: 10.7759/cureus.11108] [Reference Citation Analysis]
250 Kang I, Dong S, Lu J, Xia B. Recent Developments in HER2-Directed Therapy in Breast Cancer. Curr Breast Cancer Rep 2019;11:311-25. [DOI: 10.1007/s12609-019-00347-x] [Reference Citation Analysis]
251 Sidaway P. T-DM1 protects against invasive disease. Nat Rev Clin Oncol 2019;16:145. [PMID: 30604778 DOI: 10.1038/s41571-018-0164-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
252 Buyse M, Saad ED, Burzykowski T, Regan MM, Sweeney CS. Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy. The Oncologist 2022. [DOI: 10.1093/oncolo/oyac006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, Cortés J, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. Cancer Treat Rev 2021;103:102324. [PMID: 34953200 DOI: 10.1016/j.ctrv.2021.102324] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
254 Weiss A, King C, Grossmith S, Portnow L, Raza S, Nakhlis F, Dominici L, Barbie T, Minami C, Nimbkar S, Rhei E, Mittendorf EA, King TA. How Often Does Retrieval of a Clipped Lymph Node Change Adjuvant Therapy Recommendations? A Prospective, Consecutive, Patient Cohort Study. Ann Surg Oncol 2022. [PMID: 35041097 DOI: 10.1245/s10434-022-11324-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
255 Haussmann J, Nestle-Kraemling C, Bölke E, Wollandt S, Speer V, Djiepmo Njanang FJ, Tamaskovics B, Gerber PA, Orth K, Ruckhaeberle E, Fehm T, Corradini S, Lammering G, Mohrmann S, Audretsch W, Maas K, Roth S, Kammers K, Budach W, Matuschek C. Long-term quality of life after preoperative radiochemotherapy in patients with localized and locally advanced breast cancer. Strahlenther Onkol 2020;196:386-97. [PMID: 31919547 DOI: 10.1007/s00066-019-01557-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
256 Zeng X, Shi G, He Q, Zhu P. Screening and predicted value of potential biomarkers for breast cancer using bioinformatics analysis. Sci Rep 2021;11:20799. [PMID: 34675265 DOI: 10.1038/s41598-021-00268-9] [Reference Citation Analysis]
257 Montagna G, Lee MK, Sevilimedu V, Barrio AV, Morrow M. Is Nodal Clipping Beneficial for Node-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy? Ann Surg Oncol 2022. [PMID: 35902495 DOI: 10.1245/s10434-022-12240-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Knutson KL, Block MS, Norton N, Erskine CL, Hobday TJ, Dietz AB, Padley D, Gustafson MP, Puglisi-Knutson D, Mangskau TK, Chumsri S, Dueck AC, Karyampudi L, Wilson G, Degnim AC. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clin Cancer Res 2020;26:1045-53. [PMID: 31757875 DOI: 10.1158/1078-0432.CCR-19-2123] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
259 Zattarin E, Vernieri C. Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer. Ann Transl Med 2020;8:737. [PMID: 32647662 DOI: 10.21037/atm.2020.03.171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
260 Vahdat LT, Schmid P, Forero-Torres A, Blackwell K, Telli ML, Melisko M, Möbus V, Cortes J, Montero AJ, Ma C, Nanda R, Wright GS, He Y, Hawthorne T, Bagley RG, Halim AB, Turner CD, Yardley DA. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. NPJ Breast Cancer 2021;7:57. [PMID: 34016993 DOI: 10.1038/s41523-021-00244-6] [Reference Citation Analysis]
261 Simionescu AA, Horobeț A, Belaşcu L, Median DM. Real-World Data Analysis of Pregnancy-Associated Breast Cancer at a Tertiary-Level Hospital in Romania. Medicina (Kaunas) 2020;56:E522. [PMID: 33036248 DOI: 10.3390/medicina56100522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Sethjiwala T, Dhanushkodi M, Radhakrishnan V, Kalaiarasi JP, Mehra N, Joshi A, Rajan AK, Selvarajan G, Ananthi B, Iyer P, Senguttuvan G, Srilatha B, Ranganathan R, Sundersingh S, Krishnamurthy A, Velusamy S, Raj H, Ganesarajah S, Sagar TG, Ganesan TS. Adjuvant Short-Course Trastuzumab in Breast Cancer. Indian J Gynecol Oncolog 2019;17. [DOI: 10.1007/s40944-019-0313-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
263 Citgez B, Yigit B, Yetkin SG. Management of the Axilla and the Breast After Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review. Sisli Etfal Hastan Tip Bul 2021;55:156-61. [PMID: 34349589 DOI: 10.14744/SEMB.2021.77010] [Reference Citation Analysis]
264 Schneeweiss A, Bauerfeind I, Fehm T, Janni W, Thomssen C, Witzel I, Wöckel A, Müller V. Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. Breast Care (Basel) 2020;15:608-18. [PMID: 33447235 DOI: 10.1159/000511925] [Reference Citation Analysis]
265 Han YQ, Yi ZB, Yu P, Wang WN, Ouyang QC, Yan M, Wang XJ, Hu XC, Jiang ZF, Huang T, Tong ZS, Wang SS, Yin YM, Li H, Yang RX, Yang HW, Teng YE, Sun T, Cai L, Li HY, Ouyang XN, He JJ, Liu XL, Yang SE, Qiao YL, Fan JH, Wang JY, Xu BH. Comparisons of Treatment for HER2-Positive Breast Cancer between Chinese and International Practice: A Nationwide Multicenter Epidemiological Study from China. J Oncol 2021;2021:6621722. [PMID: 34567118 DOI: 10.1155/2021/6621722] [Reference Citation Analysis]
266 Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)-Positive Breast Cancer. JAMA Netw Open 2020;3:e2027074. [PMID: 33226431 DOI: 10.1001/jamanetworkopen.2020.27074] [Reference Citation Analysis]
267 Battisti NML, Decoster L, Williams GR, Kanesvaran R, Wildiers H, Ring A. Targeted Therapies in Older Adults With Solid Tumors. J Clin Oncol 2021;39:2128-37. [PMID: 34043448 DOI: 10.1200/JCO.21.00132] [Reference Citation Analysis]
268 An SJ, Duchesneau ED, Strassle PD, Reeder-Hayes K, Gallagher KK, Ollila DW, Downs-Canner SM, Spanheimer PM. Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer. NPJ Breast Cancer 2022;8:65. [PMID: 35552411 DOI: 10.1038/s41523-022-00433-x] [Reference Citation Analysis]
269 Grogan Fleege NM, Cobain EF. Breast Cancer Management in 2021: A Primer for the OB GYN. Best Practice & Research Clinical Obstetrics & Gynaecology 2022. [DOI: 10.1016/j.bpobgyn.2022.02.004] [Reference Citation Analysis]
270 Borsari C, Trader DJ, Tait A, Costi MP. Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology. J Med Chem 2020;63:1908-28. [PMID: 32023055 DOI: 10.1021/acs.jmedchem.9b01456] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
271 Boughey JC, Hoskin TL, Goetz MP. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. Ann Surg Oncol. [DOI: 10.1245/s10434-022-11871-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Skarping I, Blaabjerg Pedersen S, Förnvik D, Zackrisson S, Borgquist S. The association between body mass index and pathological complete response in neoadjuvant-treated breast cancer patients. Acta Oncol 2022;61:731-7. [PMID: 35363106 DOI: 10.1080/0284186X.2022.2055976] [Reference Citation Analysis]
273 Guarneri V, de Azambuja E. Anthracyclines in the treatment of patients with early breast cancer. ESMO Open 2022. [DOI: 10.1016/j.esmoop.2022.100461] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
274 Magalhães MAF, Aguiar PN, Neves MBM, Lopes GDL, del Giglio A. Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. Einstein (São Paulo) 2022;20:eGS6655. [DOI: 10.31744/einstein_journal/2022gs6655] [Reference Citation Analysis]
275 Seitz CM, Schroeder S, Knopf P, Krahl AC, Hau J, Schleicher S, Martella M, Quintanilla-Martinez L, Kneilling M, Pichler B, Lang P, Atar D, Schilbach K, Handgretinger R, Schlegel P. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology 2020;9:1683345. [PMID: 32002293 DOI: 10.1080/2162402X.2019.1683345] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
276 Kruse M, Abraham J. Advances in Care of the Breast Cancer Patient. Semin Oncol 2020;47:176. [PMID: 32624179 DOI: 10.1053/j.seminoncol.2020.06.003] [Reference Citation Analysis]
277 Batis N, Brooks JM, Payne K, Sharma N, Nankivell P, Mehanna H. Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. Adv Drug Deliv Rev 2021;176:113854. [PMID: 34192550 DOI: 10.1016/j.addr.2021.113854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
278 Ross DS, Pareja F. Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations. Surg Pathol Clin 2021;14:455-71. [PMID: 34373096 DOI: 10.1016/j.path.2021.05.009] [Reference Citation Analysis]
279 Corti C, Giugliano F, Nicolò E, Ascione L, Curigliano G. Antibody-Drug Conjugates for the Treatment of Breast Cancer. Cancers (Basel) 2021;13:2898. [PMID: 34207890 DOI: 10.3390/cancers13122898] [Reference Citation Analysis]
280 Hu X, Liu Y, Zhang X, Kong D, Kong J, Zhao D, Guo Y, Sun L, Chu L, Liu S, Hou X, Ren F, Zhao Y, Lu C, Zhai D, Yuan X. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer. Neoplasia 2020;22:539-53. [PMID: 32966956 DOI: 10.1016/j.neo.2020.08.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
281 Marquez J, Dong J, Dong C, Tian C, Serrero G. Identification of Prostaglandin F2 Receptor Negative Regulator (PTGFRN) as an internalizable target in cancer cells for antibody-drug conjugate development. PLoS One 2021;16:e0246197. [PMID: 33503070 DOI: 10.1371/journal.pone.0246197] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
282 Hu Y, Li J, Ju Y, Houston ZH, Fletcher NL, De Rose R, Fernandes S, Hagemeyer CE, Alt K, Thurecht KJ, Cortez-jugo C, Caruso F. Template-Assisted Antibody Assembly: A Versatile Approach for Engineering Functional Antibody Nanoparticles. Chem Mater . [DOI: 10.1021/acs.chemmater.1c04397] [Reference Citation Analysis]
283 Ni C, Shen Y, Fang Q, Zhang M, Yuan H, Zhang J, Zhong M, Zheng Y. Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer. Cancer Med 2020;9:2290-8. [PMID: 32017443 DOI: 10.1002/cam4.2876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
284 Martin M, Guerrero-Zotano A, Montero Á, Jara C, Filipovich E, Rojo F, Moreno F, García-Sáenz JÁ, Alés JE, Chacón JI, Cruz J, Gimenez J, Cruz-Merino L, Algara M, Santisteban M, Tarruella SL; GEICAM Spanish Breast Cancer Group Steering Committee. GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain. Oncologist 2020;25:e1339-45. [PMID: 32652782 DOI: 10.1634/theoncologist.2020-0363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
285 Pereira PMR, Norfleet J, Lewis JS, Escorcia FE. Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. J Nucl Med 2021;62:366-71. [PMID: 32646879 DOI: 10.2967/jnumed.120.244897] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
286 Hariharan N, Rao TS. The evolving role of pathologic complete response in breast cancer. South Asian J Cancer 2019;8:210-1. [PMID: 31807476 DOI: 10.4103/sajc.sajc_67_19] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
287 Stavrou E, Winer EP, Lin NU. How we treat HER2-positive brain metastases. ESMO Open 2021;6:100256. [PMID: 34482180 DOI: 10.1016/j.esmoop.2021.100256] [Reference Citation Analysis]
288 de Wild SR, Simons JM, Vrancken Peeters MTFD, Smidt ML, Koppert LB. De-Escalating Axillary Surgery in Node-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Breast Care (Basel) 2021;16:584-9. [PMID: 35087361 DOI: 10.1159/000518376] [Reference Citation Analysis]
289 Qi X, Li Y, Liu W, Wang Y, Chen Z, Lin L. Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study. Front Pharmacol 2022;13:921385. [DOI: 10.3389/fphar.2022.921385] [Reference Citation Analysis]
290 Ponzone R, Montemurro F. Extent of Breast Surgery After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Surg 2020;155:785-6. [PMID: 32401290 DOI: 10.1001/jamasurg.2020.1021] [Reference Citation Analysis]
291 Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L, Schettini F, Martínez D, Jares P, Griguolo G, Dieci MV, Cortés J, Llombart-Cussac A, Conte B, Marín-Aguilera M, Chic N, Puig-Butillé JA, Martínez A, Galván P, Tsai YH, González-Farré B, Mira A, Vivancos A, Villagrasa P, Parker JS, Conte P, Perou CM. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. EBioMedicine 2022;75:103801. [PMID: 34990895 DOI: 10.1016/j.ebiom.2021.103801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
292 Miller MS, Douglass J, Hwang MS, Skora AD, Murphy M, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Gabelli SB. An engineered antibody fragment targeting mutant β-catenin via major histocompatibility complex I neoantigen presentation. J Biol Chem 2019;294:19322-34. [PMID: 31690625 DOI: 10.1074/jbc.RA119.010251] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
293 Deken MM, Kijanka MM, Beltrán Hernández I, Slooter MD, de Bruijn HS, van Diest PJ, van Bergen En Henegouwen PMP, Lowik CWGM, Robinson DJ, Vahrmeijer AL, Oliveira S. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session. J Control Release 2020;323:269-81. [PMID: 32330574 DOI: 10.1016/j.jconrel.2020.04.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
294 Shao Y, Luo Z, Yu Y, He Y, Liu C, Chen Q, Zhu F, Nie B, Liu H. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer. Front Oncol 2022;12:939343. [DOI: 10.3389/fonc.2022.939343] [Reference Citation Analysis]
295 Başoğlu T, Özgüven S, Özkan HŞ, Çınar M, Köstek O, Demircan NC, Arıkan R, Telli TA, Ercelep Ö, Kaya H, Öneş T, Erdil TY, Uğurlu MÜ, Dane F, Yumuk PF. Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2021. [DOI: 10.1016/j.remnie.2021.05.007] [Reference Citation Analysis]
296 Bachelot T, Bailleux C, Darlix A, Jacot W. Aspects cliniques : Cancers HER2 et atteinte du système nerveux central, que faire en 2021 ?: Central nervous system metastases from HER2 positive breast cancers: what to do in 2021? Bull Cancer 2021;108:11S26-34. [PMID: 34969513 DOI: 10.1016/S0007-4551(21)00634-2] [Reference Citation Analysis]
297 Prakash I, Neely NB, Thomas SM, Sammons S, Blitzblau RC, DiLalla GA, Hyslop T, Menendez CS, Plichta JK, Rosenberger LH, Fayanju OM, Hwang ES, Greenup RA. Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer. Cancer Med 2022. [PMID: 34989142 DOI: 10.1002/cam4.4517] [Reference Citation Analysis]
298 Ben-Dror J, Shalamov M, Sonnenblick A. The History of Early Breast Cancer Treatment. Genes (Basel) 2022;13:960. [PMID: 35741721 DOI: 10.3390/genes13060960] [Reference Citation Analysis]
299 Fenn KM, Kalinsky K. Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors. Drugs Today (Barc) 2019;55:575-85. [PMID: 31584574 DOI: 10.1358/dot.2019.55.9.3039669] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
300 Assi R, Kotecki N, Awada A. Targeting molecular subtypes in solid cancers: successes and failures. Curr Opin Oncol 2020;32:488-93. [PMID: 32796233 DOI: 10.1097/CCO.0000000000000670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
301 Hope A, Wade SJ, Aghmesheh M, Vine KL. Localized delivery of immunotherapy via implantable scaffolds for breast cancer treatment. J Control Release 2021;341:399-413. [PMID: 34863842 DOI: 10.1016/j.jconrel.2021.11.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
302 Gion M, Pérez-García JM, Llombart-Cussac A, Sampayo-Cordero M, Cortés J, Malfettone A. Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. Ther Adv Med Oncol 2021;13:17588359211059587. [PMID: 34868353 DOI: 10.1177/17588359211059587] [Reference Citation Analysis]
303 Kowalczyk P, Madej A, Szymczak M, Ostaszewski R. α-Amidoamids as New Replacements of Antibiotics-Research on the Chosen K12, R2-R4 E. coli Strains. Materials (Basel) 2020;13:E5169. [PMID: 33207799 DOI: 10.3390/ma13225169] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
304 Ferrario C, Christofides A, Joy AA, Laing K, Gelmon K, Brezden-masley C. Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective. Current Oncology 2022;29:2720-34. [DOI: 10.3390/curroncol29040222] [Reference Citation Analysis]
305 Ellegård S, Engvall K, Asowed M, Hallbeck A, Elander N, Stål O. Long-term follow-up of early stage HER2-positive breast cancer patients treated with trastuzumab: A population-based real world multicenter cohort study. Front Oncol 2022;12:861324. [DOI: 10.3389/fonc.2022.861324] [Reference Citation Analysis]
306 Fares J, Kanojia D, Rashidi A, Ulasov I, Lesniak MS. Landscape of combination therapy trials in breast cancer brain metastasis. Int J Cancer 2020;147:1939-52. [PMID: 32086955 DOI: 10.1002/ijc.32937] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
307 Németh AG, Szabó R, Németh K, Keserű GM, Ábrányi-Balogh P. A stepwise one-pot synthesis of aliphatic thiols and their derivatives from acrylamides and sulfur. Org Biomol Chem 2022;20:4361-8. [PMID: 35575267 DOI: 10.1039/d2ob00512c] [Reference Citation Analysis]
308 Hong R, Xia W, Wang L, Lee K, Lu Q, Jiang K, Li S, Yu J, Wei J, Tang W, Zhou D, An X, Huang J, Xue C, Bi X, Shi Y, Yuan Z, Xu F, Wang S. Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study. Cancer Commun (Lond) 2021;41:171-82. [PMID: 33528890 DOI: 10.1002/cac2.12135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
309 Morrow M, Khan AJ. Locoregional Management After Neoadjuvant Chemotherapy. J Clin Oncol 2020;38:2281-9. [PMID: 32442069 DOI: 10.1200/JCO.19.02576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
310 Berg T, Jensen MB, Jakobsen EH, Al-Rawi S, Kenholm J, Andersson M. Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG). Breast 2020;54:242-7. [PMID: 33186804 DOI: 10.1016/j.breast.2020.10.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Yang Z, Wang W, Wang X, Qin Z. Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer. Front Pharmacol 2021;12:741451. [PMID: 34790121 DOI: 10.3389/fphar.2021.741451] [Reference Citation Analysis]
312 Gonzalez L, Mortimer J, Kruper L. De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer. Curr Breast Cancer Rep 2021;13:151-6. [DOI: 10.1007/s12609-021-00421-3] [Reference Citation Analysis]
313 Li GX, Tiulim JW, Lang JE, Kang I. Inflammatory Breast Cancer: Diagnostic, Molecular and Therapeutic Considerations. Curr Breast Cancer Rep 2019;11:335-46. [DOI: 10.1007/s12609-019-00337-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
314 Tarantino P, Curigliano G, Parsons HA, Lin NU, Krop I, Mittendorf EA, Waks A, Winer EP, Tolaney SM. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. JAMA Oncol 2022. [PMID: 35024766 DOI: 10.1001/jamaoncol.2021.6597] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
315 Guerini-rocco E, Botti G, Foschini MP, Marchiò C, Mastropasqua MG, Perrone G, Roz E, Santinelli A, Sassi I, Galimberti V, Gianni L, Viale G. Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement. Tumori. [DOI: 10.1177/03008916211062642] [Reference Citation Analysis]
316 Rubovszky G, Kocsis J, Boér K, Chilingirova N, Dank M, Kahán Z, Kaidarova D, Kövér E, Krakovská BV, Máhr K, Mriňáková B, Pikó B, Božović-spasojević I, Horváth Z. Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. Pathol Oncol Res 2022;28:1610383. [DOI: 10.3389/pore.2022.1610383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
317 Stewart P, Blanchette P, Shah PS, Ye XY, Boldt RG, Fernandes R, Vandenberg T, Raphael J. Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis. Breast 2020;54:203-10. [PMID: 33130486 DOI: 10.1016/j.breast.2020.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
318 Matuschek C, Jazmati D, Bölke E, Tamaskovics B, Corradini S, Budach W, Krug D, Mohrmann S, Ruckhäberle E, Fehm T, Nestle Krämling C, Dommach M, Haussmann J. Post-Neoadjuvant Treatment Strategies in Breast Cancer. Cancers (Basel) 2022;14:1246. [PMID: 35267554 DOI: 10.3390/cancers14051246] [Reference Citation Analysis]
319 Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G. Acquired Resistance to Antibody-Drug Conjugates. Cancers (Basel) 2019;11:E394. [PMID: 30897808 DOI: 10.3390/cancers11030394] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 13.7] [Reference Citation Analysis]
320 Fehm TN, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Lüftner D, Müller V, Schütz F, Thomssen C, Belleville E, Behrens A, Bader S, Untch M, Welslau M, Würstlein R, Thill M, Krug D, Hartkopf AD. Update Breast Cancer 2021 Part 3 - Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Frauenheilkd 2021;81:654-65. [PMID: 34168379 DOI: 10.1055/a-1487-7642] [Reference Citation Analysis]
321 Galván Morales MA, Barrera Rodríguez R, Santiago Cruz JR, Teran LM. Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy. Molecules 2020;25:E5686. [PMID: 33276556 DOI: 10.3390/molecules25235686] [Reference Citation Analysis]
322 Venetis K, Crimini E, Sajjadi E, Corti C, Guerini-rocco E, Viale G, Curigliano G, Criscitiello C, Fusco N. HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer. Front Mol Biosci 2022;9:834651. [DOI: 10.3389/fmolb.2022.834651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
323 Thomas A, Rhoads A, Suhl J, Conway KM, Hundley WG, McNally LR, Oleson J, Melin SA, Lynch CF, Romitti PA. Incidence and Survival by Human Epidermal Growth Factor Receptor 2 Status in Young Women With Stage I-III Breast Cancer: SEER, 2010-2016. Clin Breast Cancer 2020;20:e410-22. [PMID: 32278642 DOI: 10.1016/j.clbc.2020.01.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
324 Wu J, Zhao Q, Zhao Y, Zhang X, Tian Y, Guo Z. Dicer increases the indication for trastuzumab treatment in gastric cancer patients via overexpression of human epidermal growth factor receptor 2. Sci Rep 2021;11:6993. [PMID: 33772068 DOI: 10.1038/s41598-021-86485-8] [Reference Citation Analysis]
325 Aujla A, Aujla R, Liu D. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res 2019;7:9. [PMID: 31011424 DOI: 10.1186/s40364-019-0160-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
326 Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res 2021;23:84. [PMID: 34380530 DOI: 10.1186/s13058-021-01459-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
327 Pak LM, Morrow M. Addressing the problem of overtreatment in breast cancer. Expert Rev Anticancer Ther 2022;:1-14. [PMID: 35588396 DOI: 10.1080/14737140.2022.2064277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Mcgee SF, Clemons M, Savard M. Evolving Role of Risk Tailored Therapy in Early Stage HER2-Positive Breast Cancer: A Canadian Perspective. Current Oncology 2022;29:4125-37. [DOI: 10.3390/curroncol29060329] [Reference Citation Analysis]
329 Kim R, Kin T. Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease. Front Oncol 2021;11:639420. [PMID: 33816282 DOI: 10.3389/fonc.2021.639420] [Reference Citation Analysis]
330 Al-Mahayri ZN, Patrinos GP, Ali BR. Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy. Front Pharmacol 2020;11:445. [PMID: 32351390 DOI: 10.3389/fphar.2020.00445] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
331 Pogue-Geile KL, Song N, Serie DJ, Wang Y, Gavin PG, Kim RS, Tanaka N, Fumagalli D, Taniyama Y, Li Z, Rastogi P, Swain SM, Mamounas EP, Geyer CE Jr, Wolmark N, Lucas PC, Paik S, Thompson EA. Validation of the NSABP/NRG Oncology 8-Gene Trastuzumab-benefit Signature in Alliance/NCCTG N9831. JNCI Cancer Spectr 2020;4:pkaa058. [PMID: 33241186 DOI: 10.1093/jncics/pkaa058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
332 Meattini I, Livi L, Lorito N, Becherini C, Bacci M, Visani L, Fozza A, Belgioia L, Loi M, Mangoni M, Lambertini M, Morandi A. Integrating radiation therapy with targeted treatments for breast cancer: from bench to bedside. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102417] [Reference Citation Analysis]
333 Han X, Jin S, Yang H, Zhang J, Huang Z, Han J, He C, Guo H, Yang Y, Shan M, Zhang G. Application of conventional ultrasonography combined with contrast-enhanced ultrasonography in the axillary lymph nodes and evaluation of the efficacy of neoadjuvant chemotherapy in breast cancer patients. Br J Radiol 2021;94:20210520. [PMID: 34415197 DOI: 10.1259/bjr.20210520] [Reference Citation Analysis]
334 Grova MM, Strassle PD, Navajas EE, Gallagher KK, Ollila DW, Downs-Canner SM, Spanheimer PM. The Prognostic Value of Axillary Staging Following Neoadjuvant Chemotherapy in Inflammatory Breast Cancer. Ann Surg Oncol 2021;28:2182-90. [PMID: 32974693 DOI: 10.1245/s10434-020-09152-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Sauveur J, Conilh L, Beaumel S, Chettab K, Jordheim LP, Matera EL, Dumontet C. Characterization of T-DM1-resistant breast cancer cells. Pharmacol Res Perspect 2020;8:e00617. [PMID: 32583565 DOI: 10.1002/prp2.617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
336 Reimer T, Glass A, Botteri E, Loibl S, D Gentilini O. Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial. Cancers (Basel) 2020;12:E3698. [PMID: 33317077 DOI: 10.3390/cancers12123698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
337 Bhogal T, Cameron D, Palmieri C. Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review. Breast 2022;63:85-100. [PMID: 35344688 DOI: 10.1016/j.breast.2022.03.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Suppan C, Posch F, Mueller HD, Mischitz N, Steiner D, Klocker EV, Setaffy L, Bargfrieder U, Hammer R, Hauser H, Jost PJ, Dandachi N, Lax S, Balic M. Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity. Cancers (Basel) 2021;13:2492. [PMID: 34065332 DOI: 10.3390/cancers13102492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
339 Lee J, Kim JY, Bae SJ, Cho Y, Ji JH, Kim D, Ahn SG, Park HS, Park S, Kim SI, Park BW, Jeong J. The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy. Cancers (Basel) 2021;13:6205. [PMID: 34944827 DOI: 10.3390/cancers13246205] [Reference Citation Analysis]
340 Labrosse J, Osdoit M, Hamy AS, Coussy F, Pierga JY, Reyal F, Laas E. Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis. PLoS One 2020;15:e0234173. [PMID: 32502222 DOI: 10.1371/journal.pone.0234173] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
341 Pacheco Mendes A, Nogueira J, Mendes A, Cochicho J, Lavadinho I. A Case Report of an Emergency Hypertensive Episode During Trastuzumab Therapy. Cureus 2021;13:e17015. [PMID: 34522496 DOI: 10.7759/cureus.17015] [Reference Citation Analysis]
342 Li WQ, Guo HF, Li LY, Zhang YF, Cui JW. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Med 2021;10:4677-96. [PMID: 34165267 DOI: 10.1002/cam4.4052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
343 Min Y, Liu X, Hu D, Chen H, Chen J, Xiang K, Yin G, Han Y, Feng Y, Luo H. Risk Factors, Prognostic Factors, and Nomogram for Distant Metastasis in Breast Cancer Patients Without Lymph Node Metastasis. Front Endocrinol (Lausanne) 2021;12:771226. [PMID: 34899606 DOI: 10.3389/fendo.2021.771226] [Reference Citation Analysis]
344 Berger-Richardson D, Ko G, Hong NJL. Preparing for the renaissance: treating breast cancer during the COVID-19 pandemic and planning for a safe re-emergence to routine surgical care within a universal health care system. Curr Oncol 2020;27:163-8. [PMID: 32669927 DOI: 10.3747/co.27.6699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
345 Lee Chuy K, Yu AF. Cardiotoxicity of Contemporary Breast Cancer Treatments. Curr Treat Options Oncol 2019;20:51. [PMID: 31073788 DOI: 10.1007/s11864-019-0646-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
346 Sueta A, Fujiki Y, Goto-Yamaguchi L, Tomiguchi M, Yamamoto-Ibusuki M, Iwase H, Yamamoto Y. Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment. Oncol Lett 2021;22:819. [PMID: 34671433 DOI: 10.3892/ol.2021.13080] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
347 Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, Dieci MV, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, Vidal M, Brandes AA, Adamo B, Musolino A, Miglietta F, Conte B, Oliveira M, Saura C, Pernas S, Alarcón J, Llombart-Cussac A, Cortés J, Manso L, López R, Ciruelos E, Schettini F, Villagrasa P, Carey LA, Perou CM, Piacentini F, D'Amico R, Tagliafico E, Parker JS, Conte P. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncol 2020;21:1455-64. [PMID: 33152285 DOI: 10.1016/S1470-2045(20)30450-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 7.5] [Reference Citation Analysis]
348 Gameiro A, Nascimento C, Correia J, Ferreira F. HER2-Targeted Immunotherapy and Combined Protocols Showed Promising Antiproliferative Effects in Feline Mammary Carcinoma Cell-Based Models. Cancers (Basel) 2021;13:2007. [PMID: 33919468 DOI: 10.3390/cancers13092007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
349 Cao L, Xu C, Wang M, Qi W, Cai G, Cai R, Wang S, Ou D, Li M, Shen K, Chen J. Influence of Adjuvant Radiotherapy Timing on Survival Outcomes in High-Risk Patients Receiving Neoadjuvant Treatments. Front Oncol 2022;12:905223. [DOI: 10.3389/fonc.2022.905223] [Reference Citation Analysis]
350 Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF; I-SPY 2 Trial Consortium. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol 2022;23:149-60. [PMID: 34902335 DOI: 10.1016/S1470-2045(21)00589-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
351 Shay RC, Diamond JR, Kagihara JA, Sams SB. Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Breast Cancer 2021;24:106-16. [PMID: 33634625 DOI: 10.4048/jbc.2021.24.e2] [Reference Citation Analysis]
352 Viale G, Fusco N. Pathology after neoadjuvant treatment - How to assess residual disease. Breast 2021:S0960-9776(21)00990-5. [PMID: 34810049 DOI: 10.1016/j.breast.2021.11.009] [Reference Citation Analysis]
353 LeVasseur N, Li H, Cheung W, Myers P, Mckevitt E, Warburton R, Willemsma KA, Tan AD, Chia S, Simmons C. Effects of High Anxiety Scores on Surgical and Overall Treatment Plan in Patients with Breast Cancer Treated with Neoadjuvant Therapy. Oncologist 2020;25:212-7. [PMID: 32162800 DOI: 10.1634/theoncologist.2019-0512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
354 Sheng JY, Santa-Maria CA, Mangini N, Norman H, Couzi R, Nunes R, Wilkinson M, Visvanathan K, Connolly RM, Roussos Torres ET, Fetting JH, Armstrong DK, Tao JJ, Jacobs L, Wright JL, Thorner ED, Hodgdon C, Horn S, Wolff AC, Stearns V, Smith KL. Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. JCO Oncol Pract 2020;16:665-74. [PMID: 32603252 DOI: 10.1200/OP.20.00364] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
355 Solomon VR, Alizadeh E, Bernhard W, Makhlouf A, Hartimath SV, Hill W, El-Sayed A, Barreto K, Geyer CR, Fonge H. Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer. Sci Rep 2020;10:18549. [PMID: 33122707 DOI: 10.1038/s41598-020-75279-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
356 Wang L, Zhang Y, He Y, Li J, Wang T, Xie Y, Fan Z, Ouyang T. Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab. NPJ Breast Cancer 2021;7:75. [PMID: 34117262 DOI: 10.1038/s41523-021-00284-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
357 S Mano M. Trastuzumab emtansine: a game changer in HER2-positive early breast cancer. Future Oncol 2020;16:2595-609. [PMID: 32734779 DOI: 10.2217/fon-2020-0219] [Reference Citation Analysis]
358 Hatschek T, Foukakis T, Bjöhle J, Lekberg T, Fredholm H, Elinder E, Bosch A, Pekar G, Lindman H, Schiza A, Einbeigi Z, Adra J, Andersson A, Carlsson L, Dreifaldt AC, Isaksson-Friman E, Agartz S, Azavedo E, Grybäck P, Hellström M, Johansson H, Maes C, Zerdes I, Hartman J, Brandberg Y, Bergh J. Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol 2021. [PMID: 34165503 DOI: 10.1001/jamaoncol.2021.1932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
359 Fountzila E, Ignatiadis M. Neoadjuvant immunotherapy in breast cancer: a paradigm shift? Ecancermedicalscience 2020;14:1147. [PMID: 33574892 DOI: 10.3332/ecancer.2020.1147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
360 Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 2021. [PMID: 34767258 DOI: 10.3322/caac.21705] [Reference Citation Analysis]
361 Alt M, Stecca C, Tobin S, Jiang DM, Sridhar SS. Enfortumab Vedotin in urothelial cancer. Ther Adv Urol 2020;12:1756287220980192. [PMID: 33447264 DOI: 10.1177/1756287220980192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
362 Mallet A, Ombline C, Robert M, Campone M, Frenel JS. Cancer du sein HER2-low : comment un concept biologique s’immisce-t-il dans la décision thérapeutique ?: HER2-low breast cancer: how does a biological concept interfere in therapeutic decision? Bull Cancer 2021;108:11S19-25. [PMID: 34969512 DOI: 10.1016/S0007-4551(21)00633-0] [Reference Citation Analysis]
363 Williams AD, Solis O, Sterbling HM, Murray A, Sogunro O, De La Cruz LM. Are we overtreating patients with T1a HER2+ Breast Cancer? An Analysis of the National Cancer Database. Clinical Breast Cancer 2022. [DOI: 10.1016/j.clbc.2022.07.013] [Reference Citation Analysis]
364 Ganguly S, Ghosh J, Biswas B, Dabkara D. Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Indian Journal of Medical and Paediatric Oncology 2020;41:218-20. [DOI: 10.4103/ijmpo.ijmpo_246_19] [Reference Citation Analysis]
365 Igari F, Tanaka H, Giuliano AE. The Applications of Plasma Cell-free DNA in Cancer Detection: Implications in the Management of Breast Cancer Patients. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103725] [Reference Citation Analysis]
366 Jagiełło-gruszfeld AI, Rosinska M, Meluch M, Pogoda K, Niwinska A, Sienkiewicz R, Grous A, Winter P, Nowecki ZI. Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers 2022;14:1218. [DOI: 10.3390/cancers14051218] [Reference Citation Analysis]
367 Melief CJM. Special Review: The future of Immunotherapy. Immunotherapy Advances 2021;1:ltaa005. [DOI: 10.1093/immadv/ltaa005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
368 Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precis Oncol 2022;6:e2000368. [PMID: 35294223 DOI: 10.1200/PO.20.00368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Xie Y, Wu S, Zhang Y, Li J, Mo M, Shao Z, Liu G. Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer. Front Oncol 2021;11:686591. [PMID: 34168999 DOI: 10.3389/fonc.2021.686591] [Reference Citation Analysis]
370 Ang E, Wewala N, Carroll R, Forgeson G, Anderson M, Fernando J, Jordan J, Isaacs R. Neoadjuvant chemotherapy in non-metastatic breast cancer: a study on practice trends in a regional cancer treatment service. Intern Med J 2020;50:315-21. [PMID: 30989751 DOI: 10.1111/imj.14326] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
371 Wu J, Liu H, Hu T, Wang S. Gene expression trend changes in breast cancer populations over two decades: insights from The Cancer Genome Atlas database. Hereditas 2022;159:18. [PMID: 35317849 DOI: 10.1186/s41065-022-00230-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Spring L, Matikas A, Bardia A, Foukakis T. Adjuvant abemaciclib for high-risk breast cancer: the story continues. Ann Oncol 2021;32:1457-9. [PMID: 34815015 DOI: 10.1016/j.annonc.2021.10.214] [Reference Citation Analysis]
373 Chakrabarti K, Swartz LK, Gill A, Fang F, Kidwell KM, Morikawa A. Development of CNS metastases in breast cancer patients treated with curative intent: a case-control study. CNS Oncol 2020;9:CNS61. [PMID: 32945179 DOI: 10.2217/cns-2020-0012] [Reference Citation Analysis]
374 Lifrieri A, Fuzesi S, Desperito E, Taback B. When the clipped node goes missing, CT guided SAVI SCOUT placement: A novel approach for localizing soft tissue targets. Clinical Imaging 2022;85:115-7. [DOI: 10.1016/j.clinimag.2022.03.003] [Reference Citation Analysis]
375 Hurvitz SA. HER2DX: a tool that might inform treatment choices for HER2-positive breast cancer. Lancet Oncol 2020;21:1392-3. [PMID: 33152281 DOI: 10.1016/S1470-2045(20)30552-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
376 Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, DeMeo M, Burstein HJ, Partridge AH, Winer EP, Krop IE, Tolaney SM. Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer. Int J Radiat Oncol Biol Phys 2022:S0360-3016(21)03446-5. [PMID: 34990776 DOI: 10.1016/j.ijrobp.2021.12.173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
377 Aebi S, Karlsson P, Wapnir IL. Locally advanced breast cancer. Breast 2021:S0960-9776(21)01017-1. [PMID: 34930650 DOI: 10.1016/j.breast.2021.12.011] [Reference Citation Analysis]
378 Ferrando-díez A, Felip E, Pous A, Bergamino Sirven M, Margelí M. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers 2022;14:3305. [DOI: 10.3390/cancers14143305] [Reference Citation Analysis]
379 Dietz JR, Moran MS, Isakoff SJ, Kurtzman SH, Willey SC, Burstein HJ, Bleicher RJ, Lyons JA, Sarantou T, Baron PL, Stevens RE, Boolbol SK, Anderson BO, Shulman LN, Gradishar WJ, Monticciolo DL, Plecha DM, Nelson H, Yao KA. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020;181:487-497. [PMID: 32333293 DOI: 10.1007/s10549-020-05644-z] [Cited by in Crossref: 122] [Cited by in F6Publishing: 112] [Article Influence: 61.0] [Reference Citation Analysis]
380 Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 2021;18:327-44. [PMID: 33558752 DOI: 10.1038/s41571-021-00470-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 28.0] [Reference Citation Analysis]
381 Sarma M, Perimbeti S, Nasir S, Attwood K, Kapoor A, O'Connor T, Early A, Levine EG, Takabe K, Kalinski P, Ambrosone C, Khoury T, Yao S, Gandhi S. Lack of racial differences in clinical outcomes of breast cancer patients receiving neoadjuvant chemotherapy: a single academic center study. Breast Cancer Res Treat 2022. [PMID: 35000093 DOI: 10.1007/s10549-021-06506-y] [Reference Citation Analysis]
382 Early Breast Cancer Trialists’ Collaborative group (EBCTCG). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. Lancet Oncol 2021;22:1139-50. [PMID: 34339645 DOI: 10.1016/S1470-2045(21)00288-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
383 Costa RLB, Czerniecki BJ. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. NPJ Breast Cancer 2020;6:10. [PMID: 32195333 DOI: 10.1038/s41523-020-0153-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 17.0] [Reference Citation Analysis]
384 Kirwan CC, Blower EL. Contemporary breast cancer treatment-associated thrombosis. Thrombosis Research 2022;213:S8-S15. [DOI: 10.1016/j.thromres.2021.12.025] [Reference Citation Analysis]
385 Cabrera-Galeana P, Soto-Perez-de-Celis E, Reynoso-Noveron N, Villarreal-Garza C, Lara-Medina F, Alvarado-Miranda A, Espinosa-Fernandez JR, Esparza-Arias N, Mohar A, Bargallo-Rocha JE. Real-World Outcomes Among Older Mexican Women with Breast Cancer Treated with Neoadjuvant Chemotherapy. Oncologist 2020;25:1023-31. [PMID: 32275801 DOI: 10.1634/theoncologist.2019-0891] [Reference Citation Analysis]
386 Batoo S, Bayraktar S, Al-Hattab E, Basu S, Okuno S, Glück S. Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer. J Carcinog 2019;18:5. [PMID: 31949426 DOI: 10.4103/jcar.JCar_14_19] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
387 Jin W. ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications. J Clin Med 2020;9:E2255. [PMID: 32708604 DOI: 10.3390/jcm9072255] [Reference Citation Analysis]
388 Livingston-Rosanoff D, Hanlon B, Marka N, Vande Walle K, Stankowski-Drengler T, Schumacher J, Greenberg CC, Neuman H, Wilke LG. Time to initiation of neo-adjuvant chemotherapy for breast cancer treatment does not influence patient survival: A study of US breast cancer patients. Breast J 2020;26:625-9. [PMID: 31513322 DOI: 10.1111/tbj.13625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
389 de Wild SR, Simons JM, Vrancken Peeters MTFD, Smidt ML, Koppert LB; MINIMAX Group. MINImal vs. MAXimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer: Protocol of a Dutch Multicenter Registry Study (MINIMAX). Clin Breast Cancer 2021:S1526-8209(21)00199-3. [PMID: 34446364 DOI: 10.1016/j.clbc.2021.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
390 Troxell ML, Gupta T. Neoadjuvant Therapy in Breast Cancer. Surgical Pathology Clinics 2022;15:57-75. [DOI: 10.1016/j.path.2021.11.004] [Reference Citation Analysis]
391 Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen SC, Meyenberg C, Al-Sakaff N, Heinzmann D, Hegg R. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial. JAMA Oncol 2019;5:e190339. [PMID: 30998824 DOI: 10.1001/jamaoncol.2019.0339] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
392 Polley MC, Leon-Ferre RA, Leung S, Cheng A, Gao D, Sinnwell J, Liu H, Hillman DW, Eyman-Casey A, Gilbert JA, Negron V, Boughey JC, Liu MC, Ingle JN, Kalari K, Couch F, Carter JM, Visscher DW, Nielsen TO, Goetz MP. A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. Breast Cancer Res Treat 2021;185:557-66. [PMID: 33389409 DOI: 10.1007/s10549-020-06030-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
393 Gao HF, Wu Z, Lin Y, Song XY, Cao Y, Chen QJ, Zhang G, Fu P, Liu Z, Zhang LL, Yang CQ, Yang M, Zhu T, Ji F, Li JQ, Cheng MY, Wang K. Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial. Ther Adv Med Oncol 2021;13:17588359211009003. [PMID: 33959195 DOI: 10.1177/17588359211009003] [Reference Citation Analysis]
394 Malter W, Eichler C, Hanstein B, Mallmann P, Holtschmidt J. First Reported Use of Radiofrequency Identification (RFID) Technique for Targeted Excision of Suspicious Axillary Lymph Nodes in Early Stage Breast Cancer - Evaluation of Feasibility and Review of Current Recommendations. In Vivo 2020;34:1207-13. [PMID: 32354911 DOI: 10.21873/invivo.11894] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
395 Hall BJ, Bhojwani AA, Wong H, Law A, Flint H, Ahmed E, Innes H, Cliff J, Malik Z, O’hagan JE, Hall A, Sripadam R, Tolan S, Ali Z, Hart C, Errington D, Alam F, Giuliani R, Mehta S, Khanduri S, Thorp N, Jackson R, Cicconi S, Palmieri C, Mishra A. Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience. The Breast Journal 2022;2022:1-10. [DOI: 10.1155/2022/7146172] [Reference Citation Analysis]
396 Dediu M, Zielinski C. Reply to the Correspondence by Untch et al. "Concerning Dediu M, Zielinski C: A Proposal to Redefine Pathologic Complete Remission as Endpoint following Neoadjuvant Chemotherapy in Early Breast Cancer" [Breast Care 2019; DOI 10.1159/000500624]. Breast Care (Basel) 2020;15:314-6. [PMID: 32774227 DOI: 10.1159/000502508] [Reference Citation Analysis]
397 Schneeweiss A, Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Huober J, Thill M, Fasching PA, Kolberg HC, Pöschke P, Welslau M, Overkamp F, Tesch H, Fehm TN, Lüftner D, Schütz F. Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd 2020;80:277-87. [PMID: 32139917 DOI: 10.1055/a-1111-2431] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
398 Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer. J Clin Med 2019;8:E2180. [PMID: 31835708 DOI: 10.3390/jcm8122180] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
399 Salindera S, Ogilvy M, Spillane A. What are the appropriate thresholds for High Quality Performance Indicators for breast surgery in Australia and New Zealand? Breast 2020;51:94-101. [PMID: 32252005 DOI: 10.1016/j.breast.2020.01.007] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
400 Sawaki M, Shimomura A, Shien T, Iwata H. Management of breast cancer in older patients. Japanese Journal of Clinical Oncology 2022. [DOI: 10.1093/jjco/hyac054] [Reference Citation Analysis]
401 Yamashiro H, Iwata H, Masuda N, Yamamoto N, Nishimura R, Ohtani S, Sato N, Takahashi M, Kamio T, Yamazaki K, Saito T, Kato M, Lee T, Kuroi K, Takano T, Yasuno S, Morita S, Ohno S, Toi M; JBCRG-C01 Collaborative Group. Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01. Breast Cancer 2020;27:631-41. [PMID: 32060785 DOI: 10.1007/s12282-020-01057-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
402 Ban M, Petrić Miše B, Vrdoljak E. Early HER2-Positive Breast Cancer: Current Treatment and Novel Approaches. Breast Care (Basel) 2020;15:560-9. [PMID: 33447229 DOI: 10.1159/000511883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
403 Al-Tweigeri T, Elshenawy M, Badran A, Omar A, Suleman K, Al Malik O, Anwar I, Jastaniya N, Tulbah A, Al Shabanah M, Ajarim D, Al Sayed A. Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer. J Oncol 2021;2021:6639763. [PMID: 33628241 DOI: 10.1155/2021/6639763] [Reference Citation Analysis]
404 Leon-Ferre RA, Perez EA, Hillman DW, Bueno C, Perez AT, Chen B, Jenkins RB, Northfelt DW, Johnson DB, Carolla RL, Zon RT, Moreno-Aspitia A. N083E (Alliance): long-term outcomes of patients treated in a pilot phase II study of docetaxel, carboplatin, trastuzumab, and lapatinib as adjuvant therapy for early-stage HER2-positive breast cancer. Breast Cancer Res Treat 2020;182:613-22. [PMID: 32504284 DOI: 10.1007/s10549-020-05709-z] [Reference Citation Analysis]
405 Matsunaga Y, Yamaoka T, Ohba M, Miura S, Masuda H, Sangai T, Takimoto M, Nakamura S, Tsurutani J. Novel Anti-FOLR1 Antibody-Drug Conjugate MORAb-202 in Breast Cancer and Non-Small Cell Lung Cancer Cells. Antibodies (Basel) 2021;10:6. [PMID: 33535554 DOI: 10.3390/antib10010006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 Moftakhar B, Vitek W, Huston A. Impact of Breast Cancer Systemic Therapies on Fertility. Curr Breast Cancer Rep 2020;12:367-74. [DOI: 10.1007/s12609-020-00393-w] [Reference Citation Analysis]
407 Cox J, Bhatti A, Graham Y, Lee D. Update on breast cancer diagnosis and management: new topics for primary care. Br J Gen Pract 2020;70:515-6. [PMID: 33004378 DOI: 10.3399/bjgp20X712985] [Reference Citation Analysis]
408 Untch M, Thomssen C, Bauerfeind I, Braun M, Brucker SY, Felberbaum R, Hagemann F, Haidinger R, Hönig A, Huober J, Jackisch C, Kolberg HC, Kolberg-Liedtke C, Kühn T, Lüftner D, Maass N, Reimer T, Schneeweiss A, Schumacher-Wulf E, Schütz F, Thill M, Wuerstlein R, Fasching PA, Harbeck N. Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd 2019;79:591-604. [PMID: 31217628 DOI: 10.1055/a-0897-6457] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
409 Dahan M, Cortet M, Lafon C, Padilla F. Combination of Focused Ultrasound, Immunotherapy, and Chemotherapy: New Perspectives in Breast Cancer Therapy. J of Ultrasound Medicine. [DOI: 10.1002/jum.16053] [Reference Citation Analysis]
410 Zhang J, Yang Y, Chen R, Chen S, Wang J, Luo Y, Ma F, Xu B, Fan Y. Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis. Ann Transl Med 2021;9:1139. [PMID: 34430580 DOI: 10.21037/atm-21-2763] [Reference Citation Analysis]
411 Shah AN, Luck M, Goldman K, Gradishar W. Addressing Fertility: an Essential Aspect of Comprehensive Care for Young Patients with Breast Cancer. Curr Breast Cancer Rep 2020;12:381-90. [DOI: 10.1007/s12609-020-00396-7] [Reference Citation Analysis]
412 Yoon S, Go G, Yoon Y, Lim J, Lee G, Lee S. Harnessing the Physiological Functions of Cellular Prion Protein in the Kidneys: Applications for Treating Renal Diseases. Biomolecules 2021;11:784. [PMID: 34067472 DOI: 10.3390/biom11060784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
413 Perego G, Ghidini A, Luciani A, Petrelli F. Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value? Hum Vaccin Immunother 2021;:1-4. [PMID: 34856865 DOI: 10.1080/21645515.2021.1999711] [Reference Citation Analysis]
414 Morales S, Gasol A, Sanchez DR. Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments. Cancers (Basel) 2021;13:5771. [PMID: 34830927 DOI: 10.3390/cancers13225771] [Reference Citation Analysis]
415 Mahmoudi R, Dianat-Moghadam H, Poorebrahim M, Siapoush S, Poortahmasebi V, Salahlou R, Rahmati M. Recombinant immunotoxins development for HER2-based targeted cancer therapies. Cancer Cell Int 2021;21:470. [PMID: 34488747 DOI: 10.1186/s12935-021-02182-6] [Reference Citation Analysis]
416 Acevedo F, Sánchez C, Walbaum B. Terapia personalizada en cáncer de mama precoz. Implicancias prácticas. Revista Médica Clínica Las Condes 2022;33:17-24. [DOI: 10.1016/j.rmclc.2021.12.002] [Reference Citation Analysis]
417 Roy PG, Verhoeven D. Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand? Gland Surg 2020;9:1167-9. [PMID: 33224790 DOI: 10.21037/gs.2020.03.12] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
418 Tolaney SM, Partridge AH, Winer EP, Krop IE. Reply to M. Tanaka et al. J Clin Oncol 2021;39:3648-9. [PMID: 34506210 DOI: 10.1200/JCO.21.01967] [Reference Citation Analysis]
419 Deluche É, Vincent-Salomon A. « HER2-faible », un nouveau concept dans la prise en charge des cancers du sein: HER2-low breast cancer: a new concept in breast cancer treatment strategy. Bull Cancer 2021;108:11S1-7. [PMID: 34969511 DOI: 10.1016/S0007-4551(21)00631-7] [Reference Citation Analysis]
420 Liu S, Han D, Xu C, Yang F, Li Y, Zhang K, Zhao X, Zhang J, Lu T, Lu S, Shi C, Zhang R, Yang AG, Zhao A, Qin W, Yang B, Wen W. Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts. Mol Med 2022;28:37. [PMID: 35317721 DOI: 10.1186/s10020-022-00460-1] [Reference Citation Analysis]
421 Mahtani R, Oestreicher N, Lalla D, Ogbonnaya A, Saundankar V, Willey J, Coutinho AD, Mccann K. Healthcare Resource Utilization and Costs for Metastatic Breast Cancer Patients Newly Treated with Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Agents. Clinical Breast Cancer 2021. [DOI: 10.1016/j.clbc.2021.11.013] [Reference Citation Analysis]
422 Candás G, García A, Ocampo MD, Korbenfeld E, Vuoto HD, Isetta J, Cogorno L, Zimmermann AG, Sigal M, Acevedo S, Berwart J, Naveira M, Bemi A, Uriburu JL. Impact of immunohistochemical profile changes following neoadjuvant therapy in the treatment of breast cancer. Ecancermedicalscience 2021;15:1162. [PMID: 33680076 DOI: 10.3332/ecancer.2021.1162] [Reference Citation Analysis]
423 Skarping I, Förnvik D, Heide-Jørgensen U, Rydén L, Zackrisson S, Borgquist S. Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study. Acta Oncol 2020;59:1528-37. [PMID: 33063567 DOI: 10.1080/0284186X.2020.1830167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
424 Frankman ZD, Jiang L, Schroeder JA, Zohar Y. Application of Microfluidic Systems for Breast Cancer Research. Micromachines 2022;13:152. [DOI: 10.3390/mi13020152] [Reference Citation Analysis]
425 Kubo M, Kawai M, Kumamaru H, Miyata H, Tamura K, Yoshida M, Ogo E, Nagahashi M, Asaga S, Kojima Y, Kadoya T, Aogi K, Niikura N, Miyashita M, Iijima K, Hayashi N, Yamamoto Y, Imoto S, Jinno H. A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study. Breast Cancer Res Treat 2019;178:647-56. [PMID: 31451979 DOI: 10.1007/s10549-019-05413-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
426 Liu S, Mou E, Zeng S, Wang L, Dong H, Ji J, Yang H, Li J, Wang H, Li H, Xu J. Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes. Cancer Manag Res 2020;12:3145-53. [PMID: 32440212 DOI: 10.2147/CMAR.S248071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
427 Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V. Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd 2019;79:1079-89. [PMID: 31656318 DOI: 10.1055/a-1001-9925] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
428 Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet. 2019;393:2599-2612. [PMID: 31178152 DOI: 10.1016/s0140-6736(19)30650-6] [Cited by in Crossref: 91] [Cited by in F6Publishing: 51] [Article Influence: 30.3] [Reference Citation Analysis]
429 Tarantino P, Morganti S, Curigliano G. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00037] [Reference Citation Analysis]
430 Kim R, Kin T. Clinical Perspectives in Addressing Unsolved Issues in (Neo)Adjuvant Therapy for Primary Breast Cancer. Cancers (Basel) 2021;13:926. [PMID: 33672204 DOI: 10.3390/cancers13040926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Krop IE, Im SA, Barrios C, Bonnefoi H, Gralow J, Toi M, Ellis PA, Gianni L, Swain SM, Im YH, De Laurentiis M, Nowecki Z, Huang CS, Fehrenbacher L, Ito Y, Shah J, Boulet T, Liu H, Macharia H, Trask P, Song C, Winer EP, Harbeck N. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. J Clin Oncol 2021;:JCO2100896. [PMID: 34890214 DOI: 10.1200/JCO.21.00896] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
432 Caparica R, Lambertini M, Pondé N, Fumagalli D, de Azambuja E, Piccart M. Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Ther Adv Med Oncol 2019;11:1758835919827714. [PMID: 30833989 DOI: 10.1177/1758835919827714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
433 Fraguas-sánchez AI, Lozza I, Torres-suárez AI. Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic. Cancers 2022;14:1198. [DOI: 10.3390/cancers14051198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
434 Rodrigues-Ferreira S, Nahmias C. Predictive biomarkers for personalized medicine in breast cancer. Cancer Lett 2022;545:215828. [PMID: 35853538 DOI: 10.1016/j.canlet.2022.215828] [Reference Citation Analysis]
435 Sanz-Moreno A, Palomeras S, Pedersen K, Morancho B, Pascual T, Galván P, Benítez S, Gomez-Miragaya J, Ciscar M, Jimenez M, Pernas S, Petit A, Soler-Monsó MT, Viñas G, Alsaleem M, Rakha EA, Green AR, Santamaria PG, Mulder C, Lemeer S, Arribas J, Prat A, Puig T, Gonzalez-Suarez E. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer. Breast Cancer Res 2021;23:42. [PMID: 33785053 DOI: 10.1186/s13058-021-01390-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Bruxiola G, Cejalvo JM, Gambardella V, Cervantes A. In the literature: April 2019. ESMO Open 2019;4:e000513. [PMID: 31231563 DOI: 10.1136/esmoopen-2019-000513] [Reference Citation Analysis]
437 Wang S, Cui J, Fan Q, Gan J, Liu C, Wang Y, Yang T, Wang J, Yang C. Reversible and Highly Ordered Biointerfaces for Efficient Capture and Nondestructive Release of Circulating Tumor Cells. Anal Chem 2022. [PMID: 35732056 DOI: 10.1021/acs.analchem.2c01743] [Reference Citation Analysis]
438 Zhou J, Wu J, Hao X, Li P, Zhang H, Wu X, Chen J, Liu J, Xiao J, Zhang S, Jiang Z, Yang Y, Hu Z, Wang T. An exploratory study on the checkout rate of circulating tumor cells and the prediction of efficacy of neoadjuvant therapy and prognosis in patients with HER-2-positive early breast cancer. Front Oncol 2022;12:966624. [DOI: 10.3389/fonc.2022.966624] [Reference Citation Analysis]
439 Morigi C. Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20-23 March 2019: personalised treatments for patients with early breast cancer. Ecancermedicalscience 2019;13:924. [PMID: 31281421 DOI: 10.3332/ecancer.2019.924] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
440 Chien AJ, Tripathy D, Albain KS, Symmans WF, Rugo HS, Melisko ME, Wallace AM, Schwab R, Helsten T, Forero-Torres A, Stringer-Reasor E, Ellis ED, Kaplan HG, Nanda R, Jaskowiak N, Murthy R, Godellas C, Boughey JC, Elias AD, Haley BB, Kemmer K, Isaacs C, Clark AS, Lang JE, Lu J, Korde L, Edmiston KK, Northfelt DW, Viscusi RK, Yee D, Perlmutter J, Hylton NM, Van't Veer LJ, DeMichele A, Wilson A, Peterson G, Buxton MB, Paoloni M, Clennell J, Berry S, Matthews JB, Steeg K, Singhrao R, Hirst GL, Sanil A, Yau C, Asare SM, Berry DA, Esserman LJ; I-SPY 2 Consortium. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. J Clin Oncol 2020;38:1059-69. [PMID: 32031889 DOI: 10.1200/JCO.19.01027] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
441 Grassadonia A, Graziano V, Iezzi L, Vici P, Barba M, Pizzuti L, Cicero G, Krasniqi E, Mazzotta M, Marinelli D, Amodio A, Natoli C, Tinari N. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting. Cells 2021;10:1685. [PMID: 34359855 DOI: 10.3390/cells10071685] [Reference Citation Analysis]
442 Cavalcante FP, Millen EC, Zerwes FP, Novita GG. Role of Axillary Surgery After Neoadjuvant Chemotherapy. JCO Glob Oncol 2020;6:238-41. [PMID: 32073911 DOI: 10.1200/JGO.19.00351] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
443 Ladak F, Chua N, Lesniak D, Ghosh S, Wiebe E, Yakimetz W, Rajaee N, Olson D, Peiris L. Predictors of axillary node response in node-positive patients undergoing neoadjuvant chemotherapy for breast cancer. Can J Surg 2022;65:E89-96. [PMID: 35135785 DOI: 10.1503/cjs.012920] [Reference Citation Analysis]
444 Resende HM, Lichtenfels M, Soares IC, Renó AACL, Cunha AP, Falcão PG, Pieroni CSP, Assis BR, Cardoso P, Marassi PHA, Reis RDS. Sentinel lymph node biopsy using single-agent mapping tracer (blue dye) after neoadjuvant chemotherapy in a Brazilian cohort of breast cancer patients. Real world evidence. Acta Cir Bras 2021;36:e360608. [PMID: 34231654 DOI: 10.1590/ACB360608] [Reference Citation Analysis]
445 Juen L, Baltus CB, Gély C, Kervarrec T, Feuillâtre O, Desgranges A, Viaud-Massuard MC, Martin C. Therapeutic Potential of MF-TTZ-MMAE, a Site-Specifically Conjugated Antibody-Drug Conjugate, for the Treatment of HER2-Overexpressing Breast Cancer. Bioconjug Chem 2022. [PMID: 35104102 DOI: 10.1021/acs.bioconjchem.2c00015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
446 Okines AFC, Kipps E, Irfan T, Coakley M, Angelis V, Asare B, Mohammed K, Walsh G, Ring A, Johnston SRD, Parton M, Turner NC, Smith IE. Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience. Br J Cancer 2021;125:299-304. [PMID: 34017085 DOI: 10.1038/s41416-021-01428-4] [Reference Citation Analysis]
447 Guo L, Zhang H, Liu P, Mi T, Ha D, Su L, Huang L, Shi Y, Zhang J. Preclinical Assessment of Paclitaxel- and Trastuzumab-Delivering Magnetic Nanoparticles Fe3O4 for Treatment and Imaging of HER2-Positive Breast Cancer. Front Med (Lausanne) 2021;8:738775. [PMID: 34778301 DOI: 10.3389/fmed.2021.738775] [Reference Citation Analysis]
448 Ocaña A, Chacón JI, Calvo L, Antón A, Mansutti M, Albanell J, Martínez MT, Lahuerta A, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chan A, Morales S, Herranz J, Tusquets I, Chiesa M, Caballero R, Valagussa P, Bianchini G, Alba E, Gianni L. Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Front Oncol 2021;11:827625. [PMID: 35223459 DOI: 10.3389/fonc.2021.827625] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
449 Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. J Clin Oncol 2021;39:1485-505. [PMID: 33507815 DOI: 10.1200/JCO.20.03399] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 26.0] [Reference Citation Analysis]
450 Valencia GA, Neciosup S, Gómez HL, Benites MDP, Falcón S, Moron D, Veliz K, Maldonado M, Auqui R. Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context. World J Clin Oncol 2021; 12(1): 31-42 [PMID: 33552937 DOI: 10.5306/wjco.v12.i1.31] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
451 Whitehead I, Irwin GW, Bannon F, Coles CE, Copson E, Cutress RI, Dave RV, Gardiner MD, Grayson M, Holcombe C, Irshad S, O'Brien C, O'Connell RL, Palmieri C, Shaaban AM, Sharma N, Singh JK, Potter S, McIntosh SA; NeST Study Research Collaborative. The NeST (Neoadjuvant systemic therapy in breast cancer) study: National Practice Questionnaire of United Kingdom multi-disciplinary decision making. BMC Cancer 2021;21:90. [PMID: 33482770 DOI: 10.1186/s12885-020-07757-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
452 Go G, Lee SH. The Cellular Prion Protein: A Promising Therapeutic Target for Cancer. Int J Mol Sci 2020;21:E9208. [PMID: 33276687 DOI: 10.3390/ijms21239208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
453 Zhang C, Ötjengerdes RM, Roewe J, Mejias R, Marschall ALJ. Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology. BioDrugs 2020;34:435-62. [PMID: 32301049 DOI: 10.1007/s40259-020-00419-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
454 Hensing W, Santa-Maria CA, Peterson LL, Sheng JY. Landmark trials in the medical oncology management of early stage breast cancer. Semin Oncol 2020;47:278-92. [PMID: 32933761 DOI: 10.1053/j.seminoncol.2020.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
455 Paracha N, Reyes A, Diéras V, Krop I, Pivot X, Urruticoechea A. Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis. Breast Cancer Res Treat 2020;180:597-609. [PMID: 32100144 DOI: 10.1007/s10549-020-05577-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
456 de Melo Gagliato D, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, Chavez-MacGregor M. Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. Oncologist 2020;25:749-57. [PMID: 32431013 DOI: 10.1634/theoncologist.2019-0744] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
457 Piroth MD, Krug D, Sedlmayer F, Duma MN, Baumann R, Budach W, Dunst J, Feyer P, Fietkau R, Haase W, Harms W, Hehr T, Souchon R, Strnad V, Sauer R; Breast Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO). Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously? Strahlenther Onkol 2021;197:1-7. [PMID: 32737515 DOI: 10.1007/s00066-020-01667-z] [Reference Citation Analysis]
458 Artzy-Randrup Y, Epstein T, Brown JS, Costa RLB, Czerniecki BJ, Gatenby RA. Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. NPJ Breast Cancer 2021;7:26. [PMID: 33707440 DOI: 10.1038/s41523-021-00230-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
459 Zhou Q, Kyazike J, Boudanova E, Drzyzga M, Honey D, Cost R, Hou L, Duffieux F, Brun MP, Park A, Qiu H. Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues. Pharmaceuticals (Basel) 2021;14:672. [PMID: 34358098 DOI: 10.3390/ph14070672] [Reference Citation Analysis]
460 Rosenbluth JM, Overmoyer BA. Inflammatory Breast Cancer: a Separate Entity. Curr Oncol Rep 2019;21:86. [PMID: 31414257 DOI: 10.1007/s11912-019-0842-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
461 Laot L, Laas E, Girard N, Dumas E, Daoud E, Grandal B, Pierga JY, Coussy F, Kirova Y, El-Alam E, Bataillon G, Lae M, Llouquet F, Reyal F, Hamy AS. The Prognostic Value of Lymph Node Involvement after Neoadjuvant Chemotherapy Is Different among Breast Cancer Subtypes. Cancers (Basel) 2021;13:E171. [PMID: 33418983 DOI: 10.3390/cancers13020171] [Reference Citation Analysis]
462 Min Y, Feng Y, Luo H, Hu D, Wei X, He D, Yin G, Fan S. Identifying and Validating of an Autophagy-Related Gene Signature for the Prediction of Early Relapse in Breast Cancer. Front Endocrinol (Lausanne) 2022;13:824362. [PMID: 35250881 DOI: 10.3389/fendo.2022.824362] [Reference Citation Analysis]
463 Kim J, Oh JM, Lee SK, Yu J, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Kim K, Im Y. Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy. Front Oncol 2022;12:903372. [DOI: 10.3389/fonc.2022.903372] [Reference Citation Analysis]
464 Zimmer AS, Steinberg SM, Smart DD, Gilbert MR, Armstrong TS, Burton E, Houston N, Biassou N, Gril B, Brastianos PK, Carter S, Lyden D, Lipkowitz S, Steeg PS. Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases. Future Oncol 2020;16:899-909. [PMID: 32270710 DOI: 10.2217/fon-2020-0094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
465 Ueno T, Masuda N, Sato N, Ohtani S, Yamamura J, Matsunami N, Kashiwaba M, Takano T, Takahashi M, Kaneko K, Ohno S, Morita S, Toi M. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Jpn J Clin Oncol 2020;50:3-11. [PMID: 31821506 DOI: 10.1093/jjco/hyz119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
466 Tong JTW, Harris PWR, Brimble MA, Kavianinia I. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules 2021;26:5847. [PMID: 34641391 DOI: 10.3390/molecules26195847] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
467 Guan J, Zhang M. Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer. Oncol Lett 2021;21:100. [PMID: 33376533 DOI: 10.3892/ol.2020.12361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
468 Parmar V, Nair NS, Thakkar P, Chitkara G. Molecular Biology in the Breast Clinics-Current status and future perspectives. Indian J Surg Oncol 2021;12:7-20. [PMID: 33994723 DOI: 10.1007/s13193-019-00954-1] [Reference Citation Analysis]
469 Xu X, Shen S, Mo R. Bioresponsive nanogels for protein delivery. VIEW 2022;3:20200136. [DOI: 10.1002/viw.20200136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
470 Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval. Breast Cancer Res Treat 2021;187:883-91. [PMID: 33625615 DOI: 10.1007/s10549-021-06132-8] [Reference Citation Analysis]
471 Pallerla S, Abdul AURM, Comeau J, Jois S. Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer. Int J Mol Sci 2021;22:E779. [PMID: 33466691 DOI: 10.3390/ijms22020779] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
472 Schlam I, Church SE, Hether TD, Chaldekas K, Hudson BM, White AM, Maisonet E, Harris BT, Swain SM. The tumor immune microenvironment of primary and metastatic HER2- positive breast cancers utilizing gene expression and spatial proteomic profiling. J Transl Med 2021;19:480. [PMID: 34838031 DOI: 10.1186/s12967-021-03113-9] [Reference Citation Analysis]
473 Garcia-Alvarez A, Papakonstantinou A, Oliveira M. Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies. Cancers (Basel) 2021;13:2927. [PMID: 34208287 DOI: 10.3390/cancers13122927] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
474 Cobert AM, Helms C, Larck C, Moore DC. Risk of hepatotoxicity with trastuzumab emtansine in breast cancer patients: a systematic review and meta-analysis. Ther Adv Drug Saf 2020;11:2042098620915058. [PMID: 32341779 DOI: 10.1177/2042098620915058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
475 Erickson AW, Habbous S, Hoey C, Jerzak KJ, Das S. Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis. NPJ Breast Cancer 2021;7:17. [PMID: 33602948 DOI: 10.1038/s41523-021-00220-0] [Reference Citation Analysis]
476 Stankowski-Drengler TJ, Schumacher JR, Hanlon B, Livingston-Rosanoff D, Van de Walle K, Greenberg CC, Wilke LG, Neuman HB. Outcomes for Patients with Residual Stage II/III Breast Cancer Following Neoadjuvant Chemotherapy (AFT-01). Ann Surg Oncol 2020;27:637-44. [PMID: 31900808 DOI: 10.1245/s10434-019-07846-2] [Reference Citation Analysis]
477 Benson JR, Dumitru D, Jatoi I. Highlights of the San Antonio Breast Cancer Symposium 2019 Part 2: the challenges of tumor heterogeneity. Future Oncol 2020;16:1503-9. [PMID: 32469673 DOI: 10.2217/fon-2020-0310] [Reference Citation Analysis]
478 Rabe L, Wenz F, Ehmann M, Lohr F, Dieter Hofheinz R, Buergy D. Radiotherapy and newly approved cancer drugs – A quantitative analysis of registered protocols for drugs approved for the treatment of solid tumors. Radiotherapy and Oncology 2022. [DOI: 10.1016/j.radonc.2022.01.025] [Reference Citation Analysis]
479 Li Y, Zhou Y, Mao F, Lin Y, Zhang X, Shen S, Sun Q. The Diagnostic Performance of Minimally Invasive Biopsy in Predicting Breast Pathological Complete Response After Neoadjuvant Systemic Therapy in Breast Cancer: A Meta-Analysis. Front Oncol 2020;10:933. [PMID: 32676452 DOI: 10.3389/fonc.2020.00933] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
480 Omarini C, Bettelli S, Manfredini S, Barbolini M, Isca C, Cortesi G, Maiorana A, Tazzioli G, Dominici M, Piacentini F. Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy. Transl Oncol 2020;13:100794. [PMID: 32485588 DOI: 10.1016/j.tranon.2020.100794] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
481 Livingston-Rosanoff D, Schumacher J, Vande Walle K, Stankowski-Drengler T, Greenberg CC, Neuman H, Wilke LG. Does Tumor Size Predict Response to Neoadjuvant Chemotherapy in the Modern Era of Biologically Driven Treatment? A Nationwide Study of US Breast Cancer Patients. Clin Breast Cancer 2019;19:e741-7. [PMID: 31300338 DOI: 10.1016/j.clbc.2019.05.014] [Reference Citation Analysis]
482 Bailleux C, Eberst L, Bachelot T. Treatment strategies for breast cancer brain metastases. Br J Cancer 2021;124:142-55. [PMID: 33250512 DOI: 10.1038/s41416-020-01175-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]